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11 incretins
There are two main incretin hormones in humans, glp-1 (glucagon-like pep-
tide-1) and gip (glucose-dependent insulinotropic peptide, also known as 
gastric inhibitory peptide). Both hormones are secreted by endocrine cells 
that are located in the epithelium of the small intestine. Food intake, and also 
stimulation of the sympathetic nervous system (for example physical exercise), 
stimulate the secretion of glp-1 and is rapidly inactivated by enzyme dpp-iv 
(Dipeptidyl peptidase-iv). The mechanism of incretin action is outlined in 
Figure 2. glp-1 stimulates the production and secretion of insulin, the release 
of somatostatin, and glucose utilization by increasing insulin sensitivity. It 
inhibits glucagon release, gastric emptying, appetite, and food intake via the 
central nervous system [4].
balance between glucose production and utilization
In the postabsorptive state plasma glucose levels are the result the balance 
between the rates of glucose production and glucose utilization [5]. Each of 
these processes is tightly regulated by the levels of hormones and substrates 
in blood. Glucose is produced by both the liver (90%) and the kidneys (10%). 
The kidneys take up ~10% of the glucose produced, so that in a net sense they 
do not supply glucose to the other tissues of the body. Therefore, the liver is 
responsible for providing glucose to both insulin-insensitive (neural tissues, 
formed elements of the blood, skin, smooth muscle, etc.) and insulin-sensitive 
(skeletal muscle and fat) tissues. The control of hepatic glucose production 
(hgp) by the liver serves as a primary regulatory event of glucose homeostasis. 
In normal physiology the liver maintains blood glucose homeostasis by rapid 
clearance of glucose from the portal vein in the absorptive state after a meal 
(glycogenesis), and by controlled production of glucose (gluconeogenesis & 
glycogenolysis) in the fasted state at a sufficient rate to maintain euglycemia 
(blood glucose level 4.5-6.5 mmol/L) [6]. 
diabetes mellitus type 2 (t2dm) 
Type 2 diabetes mellitus (t2dm) is a characterized by a combination of resis-
tance to insulin action in target tissues and inadequate compensatory insulin 
secretion. In the absence of a defect in ß-cell function, individuals can com-
pensate for insulin resistance with appropriate hyperinsulinemia. However, 
in a later stage of the disease, a decline in pancreatic ß-cell function (relative 
insulin deficiency) ultimately leads to postprandial and fasting hyperglycemia 
glucose homeostasis 
The pancreatic islets of Langerhans secrete the reciprocal hormones insulin 
and glucagon which are responsible for controlling of the glucoregulatory 
feedback-loop and tightly control blood glucose levels (Figure 1). Insulin is pro-
duced by the ß-cells of the pancreas and was first discovered in 1921 by Dr. 
Frederick Banting and Charles Best. Shortly after the discovery of insulin, glu-
cagon hormone, which is secreted from pancreatic α-cells, was discovered by 
Kimball and Murlin [1]. 
insulin regulates carbohydrate, protein and fat 
metabolism in the body
Insulin binds to tyrosine kinase receptors at the cell surface. Insulin inhibits 
hepatic glucose production and stimulates glycogenesis, the process of gly-
cogen synthesis for storage in liver and muscles. Glucose uptake is increased 
by insulin, which stimulates the transport of vesicles containing glucose 
transporters towards the cell membrane. Furthermore, insulin inhibits glu-
cagon secretion from pancreatic α-cells, thereby decreasing hepatic glucose 
production (gluconeogenesis and glycogenolysis). Adipose tissue is exqui-
sitely sensitive to the inhibitory effect of insulin on lipolysis. Insulin decreases 
the release of nonesterified fatty acids and glycerol from adipose tissue and 
gluconeogenic precursors from skeletal muscles, thus causing a decrease in 
precursor supply for hepatic gluconeogenesis. 
glucagon protects against hypoglycemia
The main role of glucagon is to protect the body and in particular the brain 
from low glucose levels during periods of fasting. In healthy subjects, gluca-
gon levels are only elevated in the fasting state, because low glucose levels 
are the most important physiologic stimulator of glucagon secretion. Glucagon 
mediates its effects by binding to and activating the glucagon receptor (gcgr), 
a member of the class B family of heptahelical gtp-binding protein coupled 
receptors [2]. Stimulation of these receptors results in activation of adenylate 
cylase and increased levels of intracellular cyclic adenosine monophosphate 
(camp). Glucagon receptors are mainly expressed in the liver and kidney with 
lesser amounts in heart, adipose tissue, adrenal glands, pancreas, cerebral cor-
tex and gastrointestinal tract [2;3]. The role of gcgr in glucose homeostasis 
has been studied in mice lacking the receptor, which show slightly reduced 
plasma levels of glucose and insulin. Agonism at the glucagon receptor results 
in glycogenolysis, gluconeogenesis, proteolysis and lipolysis.
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11 current insulin-based therapies
Standard pharmacological, insulin-based, treatment regimens for t2dm are 
oral blood glucose lowering medication as biguanides, sulfonylureas, and/or 
thiazolidinediones. In the 1950’s, the biguanide drug metformin was introduced 
for the treatment of diabetes as insulin sensitizer by increasing the efficiency of 
glucose transporters and lowering glycated hemoglobin (HbA1c) by 1–2% [32]. 
Gastrointestinal side-effects occur to varying degrees in up to 30% of patients. 
Sulphonylureas act mainly by stimulating insulin release from the ß-cells of the 
pancreas and may also improve insulin resistance in peripheral target tissues. 
These drugs reduce concentrations of HbA1c by 1–2% and fasting plasma glu-
cose (fpg) concentrations by 3.3–3.9 mmol/L [33]. Hypoglycemia is the most 
worrisome side effect of the sulfonylureas. Thiazolidinediones (tzd), such as pi-
oglitazone, have been associated with a 0.5 to 1.5 % reduction in HbA1c levels 
and 1.4 to 2.8 mmol/L reductions in fpg levels. tzd’s are contraindicated in pa-
tients with (a history of) heart failure and should be used with caution in women 
at high risk of fractures [34]. Currently, tzds are hardly prescribed any more in 
the Netherlands. In a more advanced stage of the disease, exogenous subcu-
taneous insulin therapy or a combination of subcutaneous insulin with oral 
drugs will be prescribed. Although insulin therapy results in a 1-2% reduction of 
HbA1c, it is accompanied by weight gain, a significant risk of hypoglycemia and 
an increased risk of cancer in patients taking long-acting insulin [32].
current incretin-based therapies
Almost 10 years ago, incretin-based therapies (glp-1 analogs or dpp-iv inhibi-
tors) were introduced on the market for overweight t2dm patients [35]. t2dm 
patients display an impaired incretin effect and higher glp-1 levels can be 
achieved using glp-1 analogs, glp-1 receptor agonists produced by recom-
binant dna technology or ddp-iv inhibitors which prolong the half-life of 
endogenous glp-1 by preventing its enzymatic degradation. In 2005 exenatide 
was the first fda (Food and Drug Administration, usa) approved drug that uses 
the ‘incretin effect’. Currently available glp-1 analogs exenatide and liraglutide 
have to be administered subcutaneously; exenatide twice daily and liraglutide 
once a day. Recently, exenatide has been developed in an extended-release 
formulation which can be used once weekly. Clinical trials with exenatide [36-
39] showed significant reductions in HbA1c of approximately 1.0–1.2% when 
compared to placebo, and a modest reduction in fasting plasma glucose (fpg) 
of approximately 1.0–1.4 mM. The average weight loss amounted to 1.6 kg in 
the exenatide-treated groups. Liraglutide significantly lowered HbA1c by 0.8–
1.5%, fpg with up to 2.6 mM, and induced a weight loss in the range of 2 to 3 kg 
compared to the placebo-treated group [39-41]. In lead 6 study both available 
exploring the role of glucagon in glucose homeostasis
10
that characterizes t2dm. Insulin resistance prolongs the duration of postpran-
dial hyperglycemia, which can be marked when both hepatic and extra-hepatic 
insulin resistance are present [7]. Studies using hyperinsulinemic euglycemic 
clamps show impaired suppression of hepatic glucose production by hyper-
glycemia [8] and by elevated insulin levels [9], indicating that intrahepatic 
changes in glucose metabolism and in responsiveness to hyperglycemia and 
insulin contribute to the increase in the hepatic glucose threshold and insulin 
resistance.
In addition, subjects with t2dm have elevated fasting glucagon concentra-
tions that do not decrease appropriately, and can even paradoxically increase, 
after food ingestion [10-13]. During fasting conditions in t2dm patients, 
hyperglucagonemia sustains gluconeogenesis and glycogenolysis in the liver, 
contributing to increased fasting blood glucose levels [14]. Similarly, increased 
glucagon responses after food ingestion, result in inadequate suppression 
of hepatic glucose production, contributing to increased postprandial glu-
cose levels [11]. This paradoxical glucagon response may be explained by an 
impaired suppressive effect of glucose on the α-cell in t2dm and by gastro-
intestinal factors as reduced incretin effect observed in patients with t2dm 
[15]. Knop et al. showed attenuated and delayed glucagon suppression in t2dm 
after oral ingestion of glucose, where intravenous administration of the same 
amount of glucose results in normal suppression of glucagon, supporting this 
hypothesis  [15].
glycaemic control / treatment of t2dm
The Diabetes Control and Complications Trial [16] and the U.K. Prospective 
Diabetes Study [17;18] have documented that strict glycemic control effec-
tively reduces the risk of developing microvascular (diabetic nephropathy, 
neuropathy, and retinopathy) and, to a lesser extent, macrovascular (coronary 
 artery disease, peripheral arterial disease, and stroke) complications of diabe-
tes. Current treatments for t2dm are focused on increasing insulin secretion 
or improving insulin sensitivity. Lifestyle modifications such as diet, are con-
sidered the first line of treatment to halt or delay further progression of the 
disease [19]. In addition to energy intake restriction, specific food compo-
nents like amino acids and proteins can be applied to more directly modulate 
glycemic control. The possibility that substances other than glucose could 
stimulate insulin secretion was first reported by Cochrane et al. in 1956 [20]. 
Subsequently, many studies have demonstrated that the combined intake of 
carbohydrate and protein induced a higher insulin response than the intake 
of carbohydrate alone [21;22], both in healthy subjects [23-25] and in t2dm 
patients [26-31]. 
exploring the role of glucagon in glucose homeostasis
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11 novel mechanism(s) of action for the treatment of 
diabetes type 2
Despite all currently available pharmacological therapies, treatment of patients 
with diabetes is not completely successful in restoring control of glucose 
metabolism. Thus, there remains a need for agents with novel mechanism(s) of 
action. Nowadays, there is more attention to the role of liver in the pathogen-
esis of diabetes, reduction of hepatic glucose production has been targeted as 
a strategy for diabetes treatment and can be achieved through counteracting 
the action of glucagon. Attenuation of the action of glucagon could be a viable 
therapeutic strategy for t2dm in combination with insulin-based antidiabetic 
drugs that are currently on the market (combined targeting of two sites within 
the liver).
glucagon receptor antagonists
Pharmacological antagonism of glucagon action may be a potential thera-
peutic approach for t2dm. Different mechanisms to lower glucagon levels 
are: inhibition of glucagon secretion, gcgr receptor blockers and (antisense) 
inhibition of gcgr expression. Peptide antagonists and monoclonal antibod-
ies against the gcgr attenuated hyperglycemia in animal models [49-51], 
suggesting a potential to treat hyperglycemia in t2dm through the inhibition 
of glucagon function. Peptides were the earliest gcgr antagonists that were 
designed by structural modification of the native hormone [52] . However, oral 
bioavailability and long half-life appeared to be hurdles that have not been 
overcome. The development of small molecules against the gcgr has not been 
very successful due to limited drug selectivity, cross-species differences and 
lack of sustained effects after non-competitive blockade [53]. Only one phase 1 
study has been published describing the acute effects of Bay 27-9955, a small 
molecule glucagon receptor inhibitor [54] that blunted hyperglucagonemia-
induced hyperglycemia. However, long-term antidiabetic benefits, as well as 
side effects, of this compound in patients with t2dm remain unknown. 
antisense therapy
Antisense oligonucleotides (asos) as therapeutical agents are relatively 
new, and only one antisense compound has been approved by the fda and 
European authorities until now [55]. Many antisense compounds are currently 
in preclinical or clinical development phases. asos are short, single-stranded 
molecules which are complementary to a target messenger ribonucleic acid 
(mrna). Upon Watson-Crick hybridization with their target mrna, asos inhibit 
glp-analogs were compared [42]. The mean reduction in HbA1c levels was 
significantly higher with liraglutide 1.8 mg once daily than with exenatide 10 
mg twice daily (−1.12% versus −0.79%; p<0.001). The most common adverse 
events associated with glp-1 mimetics are gastrointestinal. Safety concerns 
have been raised during the development of liraglutide; a small number of 
cases of pancreatitis have been reported [43], while the initial concerns regard-
ing thyroid C-cell tumors have not been confirmed in humans [44]. In contrast 
to glp-1 receptor agonists, dpp-iv inhibitors are orally available and have a 
longer duration of action, requiring only once daily dosing. Sitagliptin, vilda-
gliptin, saxagliptine, and linagliptine as monotreatment and also combined 
with metformin are currently available in the Netherlands. These drugs control 
hyperglycemia, reduce HbA1c concentrations by ~1%, and improve pancreatic 
ß-cell function. dpp-iv inhibitors are generally safe and well-tolerated with a 
low risk of hypoglycemia, but do not reduce appetite or cause weight loss such 
as glp-1 agonists [45]. The long-term safety and effects of glp-1 analogs and 
dpp-iv inhibitors have not been established yet.
sglt2 inhibitors in the treatment of type 2 diabetes
Agents that inhibit sodium glucose co-transporter 2 (sglt2) in the kidney 
represent a novel class of drugs, which has become available for treatment of 
t2dm since 2012. The sglt2 transporter protein is found only in renal epithe-
lium cells of the proximal tubule, and mediates the majority (~90%) of glucose 
reabsorption along the nephron. Pharmacological inhibition of sglt2 increases 
urinary glucose excretion and decreases plasma glucose levels in an insulin-
independent manner [46]. Hypoglycemic episodes are less likely, because of 
the insulin independence of their action plus the fact that these compounds 
only lower the glucose re-absorption threshold without completely blocking 
renal glucose reabsorption. In November 2012 the first sglt2 inhibitor dapa-
gliflozine was introduced on the market in Europe, followed by canagliflozine 
in September 2013. In the usa canagliflozin became the first sglt2 inhibitor 
(approved March 2013), followed by dapagliflozine which was approved in 
January 2014 by the fda. Clinical trials on these two agents have shown signifi-
cant and sustained HbA1c reduction of 0.5-1% when used as monotherapy or 
in combination with other antidiabetic agents [47]. Comparing other antidia-
betic drugs, the major disadvantage of sglt2 inhibitors is the increased risk of 
genital mycotic infections and urinary tract infections, particularly in women. 
Additionally, since the efficacy of sglt2 inhibitors requires adequate filtered 
load of glucose in the kidney, their efficacy diminishes in renal impairment. 
Multiple other sglt2 inhibitors are currently in clinical development such as 
small molecules empagliflozin, ipragliflozin, lx4211 (a novel dual inhibitor of 
sglt1 and sglt2 glucose transporters), and antisense oligonucleotide target-
ing the human sglt2 transporter [48].
exploring the role of glucagon in glucose homeostasis
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Furthermore, we determined whether human adipose tissue expresses gluca-
gon receptor mrna.
In chapter 4 the effects of a glucagon challenge in t2dm patients were 
explored. A stable isotope glucose tracer technique was applied to determine 
hepatic glucose production. The influence of oral antidiabetic drugs on the 
response to hyperglucagonemia was investigated by using a cross-over study 
design. We compared the glucagon challenge data of healthy volunteers with 
t2dm.
Increased fasting and post-meal glucagon concentrations cause excessive 
hepatic glucose production (hgp) in patients with type 2 diabetes, suggesting 
that attenuation of hepatic glucagon action could be a promising therapeutic 
strategy for t2dm. chapter 5 shows the results of the phase I double-blind, 
placebo-controlled, dose-escalation study, which evaluated the safety, toler-
ability, pk and pharmacodynamics of single and multiple dose administrations 
of placebo or antisense glucagon receptor antagonist (isis 325568) at 4 dose 
levels in healthy subjects. In the multiple dose cohorts at each dose level, 8 
subjects received 8 doses over 6-weeks (3 iv doses in week 1 followed by 5 
weekly sc doses) and underwent a glucagon challenge procedure (glucagon 
infusion that doubled both plasma glucagon and glucose levels) at baseline 
and at the end of 6-week treatment.
chapter 6 describes the development of a semi-mechanistic model simul-
taneously describing glucagon, plasma glucose, insulin and glucagon receptor 
internalization. This model was build using data from our glucagon challenge 
study in healthy volunteers (chapter 3).
Finally, chapter 7 combines the results and conclusions from the previous 
chapters and places these in a broader perspective. The role of glucagon in 
glucose homeostasis in health and disease is discussed and suggestions for 
future research are given.
translation through the activation of endogenous rnase h enzymes and other 
mechanisms, for example via alternative splicing (Figure 3) [56]. 
clinical use of antisense oligonucleotides (asos)
For clinical use of asos, chemical modified asos were used. The first generation 
oligonucleotides contain a phosphorothioate modification to protect the mol-
ecule from rapid degradation by nucleases. Second-generation 2’-O-methyl 
(2’-ome) and 2’-methoxyethyl (2’-moe) oligonucleotides were developed to 
further increase nuclease resistance, thereby improving pharmacokinetics 
and to increase target affinity. Third-generation oligonucleotides represent a 
heterogeneous group of asos that are most often dna and rna analogs with 
modified phosphate linkages or riboses. These modifications also lead to 
improved nuclease resistance, affinity and pharmacokinetics. The different 
classes of asos have different toxicological, pharmacokinetic and pharmaco-
logical properties [57;58]. Studies with species-specific gcgr antisense drugs 
in rodent models of t2dm have demonstrated selective inhibition of hepatic 
and adipose tissue glucagon receptor expression and normalization of blood 
glucose levels without development of hypoglycemia or weight gain [59;60]. In 
addition to hepatic effects, in preclinical studies glucagon receptor antisense 
therapy increased the levels of active glp-1 levels and improved pancreatic 
beta cell function [60].
In conclusion, the pathophysiology of t2dm is characterized not only by 
insulin resistance and ß-cell dysfunction, but also with elevated fasted and 
postprandial plasma glucagon levels. It has been suggested that the diabetic 
α-cell exhibits a reduced glucose sensitivity and/or insulin resistance. The 
overall aim of this thesis was to gain more insight in the role of glucagon in glu-
cose homeostasis in health and disease, and to explore glucagon antagonism 
as therapeutic potential for the treatment of t2dm.
outline of this thesis
This thesis is comprised of a variety of human studies designed to investigate 
the role of glucagon in glucose homeostasis in health and disease. 
chapter 2 studied the effects of a single protein hydrolysate meal replace-
ment (insuVida™) on postprandial serum glucose, insulin and glucagon levels 
in patients with type 2 diabetes. 
The aim of the study in chapter 3 was to characterize the applicability of 
the glucagon challenge test as a tool in diabetes research, by assessing the 
inter- and intra-individual variabilities of the glucagon challenge test and 
investigating the activity of the autonomic nervous system (ans) during the 
challenge, as this might have an indirect impact on glucose homeostasis. 
general introduction and outline of the thesis
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figure 1 Homeostatic insulin-glucagon system 
Diagram of the homeostatic (insulin-glucagon) system. Insulin secretion is 
stimulated by high blood glucose levels and glucagon is stimulated by low 
blood glucose levels.
figure 2 Enteroinsulinar axis
After food intake (1) the complex sugars are broken down in the small intestine 
into glucose molecules. L-cells in the distal intestinal wall secrete the incretin 
glp-1 upon stimulation by food/glucose (2). This glucagon-like peptide-1 
is released proportional to the amount of food post-prandial in the distal 
intestine. glp-1 is key player in many processes after a meal. It stimulates the 
release of insulin by the ß-cells in the pancreas (3). Similarly, glp-1 inhibits 
the release of glucagon by the α-cells (4). The rise in insulin will stimulate the 
glucose uptake from the blood into the cells (8). Further, glp-1 inhibits gastric 
emptying (5) and induces the feeling of satiety (6) in order to reduce further 
carbohydrate intake. glp-1 is metabolised by the enzyme dipeptidyl peptidase 
4 (ddp-iv) which is present in the cell wall (7).
figure 3 Antisense oligonucleotides
rnase h-dependent antisense mechanism. Single-stranded oligonucleotides 
are transported across the plasma membrane, by either poorly characterized 
natural processes or by the use of facilitators such as cationic lipids (step 1). 
Once in the cytoplasm, single-stranded oligonucleotides rapidly accumulate 
in the cell nucleus (steps 2 and 3), where they bind to their targeted rna (step 
4). Once bound to the rna, rnase h recognizes the oligonucleotide/rna 
duplex as a substrate, cleaving the rna strand and releasing the antisense 
oligonucleotide (step 5). Although the cleavage of the rna by rnase h is 
shown to occur in the nucleus, rnase h is also present in the cytosol, allowing 
for cleavage to occur in that cellular compartment as well.
See inside of the backcover for the figures in full colour.
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background Lifestyle modifications, including diet, are important in the 
prevention and management of type 2 diabetes mellitus (t2dm). However, lim-
ited information is available on the effects of single doses of meal replacements, 
particularly with regard to their effect on postprandial glucose. Therefore a 
study was performed comparing the effects of a single meal replacement in 
t2dm patients on postprandial serum glucose, insulin and glucagon. 
methods This randomized, double-blind, partial cross-over study was per-
formed in 36 t2dm patients who continued their oral anti-diabetic medication. 
Each patient received three out of four treatments separated by 7 days. The 
treatments were a proprietary casein hydrolysate (insuVida™) alone or with 
additional leucine, unhydrolysed casein or placebo. Blood sampling was done 
for 4 hrs. Treatments were compared using repeated measures anova. Results 
are given as an estimate of the difference (%) for the 4 hrs epoch.
results Glucose concentrations were lowered by 4.7% by insuVida™ and 
insuVida™ plus added leucine compared to placebo (95%ci: -1.6% to -7.7%) 
while the effect of unhydrolysed casein was -1.7% (-4.8% to 1.5%). Addition of 
leucine to insuVida™ induced the greatest increase in insulin (51.8%; 41.1% to 
63.4%). All three treatments increased glucagon concentrations by 14% (8% 
to 20%) compared to placebo.
conclusions A single dose of insuVida™ with or without addition of leucine 
significantly lowered plasma glucose compared to placebo and intact casein in 
t2dm patients. This is most likely due to an insulinotropic effect of insuVida™. 
The data suggest that this type of intervention may be a viable treatment strat-
egy in t2dm.
introduction
Lifestyle modifications such as diet, have beneficial effects on glucose metab-
olism in type 2 diabetes mellitus (t2dm) and are considered the first line of 
action to halt or delay further progression of the disease [1]. The development 
of ingredients for a functional food could be an interesting addition to the cur-
rent dietary recommendations. Patients with t2dm can be characterised in 
part by impaired insulin response upon intake of carbohydrates such as glu-
cose. Therefore, insulin secretagogues such as sulfonylurea derivatives are an 
important class of antidiabetic medication [2]. Amino acids are known to have 
insulinotropic properties as well [3-5]. The possibility that substances other 
than glucose could stimulate insulin secretion was first reported by Cochrane 
et al. in 1956, who showed that casein ingestion could induce acute hypogly-
cemia in children with familial idiopathic hypoglycemia [6]. Subsequently, 
many studies have demonstrated that the combined intake of carbohydrate 
and protein induced a higher insulin response than the intake of carbohydrate 
alone [7;8], both in healthy subjects [9-11] and in t2dm patients [12-17]. 
Specific amino acids, such as leucine, have been shown to further augment 
the insulin response of protein co-ingestion in healthy subjects [11;18] and 
type 2 diabetes mellitus patients [17;19]. Leucine stimulates insulin secretion 
in pancreatic ß-cells by increasing mitochondrial metabolism by activation 
of glutamate dehydrogenase (gdh) and increasing atp (adenosinetrifosfaat) 
production by transamination of leucine [20;21]. Although the hypoglycaemic 
effect of proteins was first noted in the 1960s [7;8], a practical application of 
this effect has only been explored more thoroughly during the last ten years. 
One of these applications is the use of a protein hydrolysate as a meal replace-
ment. Research with the proprietary casein hydrolysate insuVida™ (insV, 
formerly known as InsuVital™) has shown that ingestion of this product with 
carbohydrate augments the insulin response and enhances glucose disposal 
in patients with long-standing t2dm [12;15;19], which makes it an attractive 
food-based intervention. However, some of these studies were performed 
using a fairly high amount of protein (25-85 gram protein). Hence, these inter-
ventions were associated with a high protein load which would be undesirable 
in a subset of patients with diabetes mellitus who may have an impaired renal 
function. The addition of a protein hydrolysate could be used in a functional or 
clinical food for diabetic subjects if lower amounts of protein would also pro-
duce significant benefits in terms of glucose management. However, efficacy 
at a lower dose has not previously been demonstrated and therefore further 
research is needed to compare intact protein versus protein hydrolysate and 
on the additional effect of leucine on glucose homeostasis. Therefore, in a 
randomized, double-blind, placebo-controlled, partial cross-over study, we 
compared the insulinotropic, glycaemic and glucagonaemic effects of a low 
dose of a proprietary casein hydrolysate, with and without added leucine, 
against its native intact protein in individuals with stable-treated type 2 diabe-
tes. The patients continued their medication in order to demonstrate whether 
the effects of the hydrolysate could add beneficial effects on top of medication.
methods
The study was conducted in accordance with the Declaration of Helsinki and 
Guideline for Good Clinical Practice. The protocol of this study was approved by 
the Medical Ethics Committee of the Leiden University Medical Center (lumc). 
After informed consent was obtained, all patients were screened approximate-
ly three weeks before start of the study to assess eligibility. Screening consisted 
of a medical examination, ecg, vital signs, standard urine analysis and, hema-
tology, virology, chemistry and HbA1c laboratory tests. 
exploring the role of glucagon in glucose homeostasis
22




The study was performed in 36 patients of either gender, between 50 and 70 
years of age and with an established diagnosis of t2dm as evidenced by the 
use of oral antidiabetic medication for at least one year and a fasting plasma 
glucose concentration of ≥ 7.0 mmol/L at screening after abstaining from 
oral antidiabetic medication for at least two days. Exclusion criteria were use 
of insulin, body mass index (bmi) > 35 kg/m², (recent) pregnancy, significant 
history of ischemic heart disease or congestive heart failure, uncontrolled 
hypertension, severe diabetic retinopathy, impaired liver function or renal 
function. After inclusion, patients were randomized according to the procedure 
described by Wakeling and MacFie [22]. A partial cross-over design was chosen 
in which each participant received three out of the four possible treatments 
with wash-out periods of 7 days. This was chosen to decrease the burden for 
the patient without under-powering the study.
treatments
The interventions were offered as a breakfast meal replacement shake that 
was freshly prepared prior to use by dissolving a sachet with 300 mL cold water. 
The treatments were administered between 9.00 and 9.30 am. The energy con-
tent of the shakes was standardized and comparable with a normal breakfast. 
No information on the composition of the contents in the sachets was visible 
for either the participants or the research staff. Three out of the following four 
treatments were given (Table 1): 
 » Placebo
 » Unhydrolysed casein
 » insuVida™ (insV)
 » insuVida™+leucine (insV+leu)
For each of the treatments the amount of carbohydrate, fat and vitamins was 
identical, except for the addition of 0.25 mg chromium picolinate and minerals 
for the insV treatments. All beverages were uniformly lemon flavoured. insu-
Vida™ (dsm Food Specialties, Delft, The Netherlands) is a casein hydrolysate 
which is obtained by enzymatic hydrolysis of sodium caseinate. The amount 
and composition of the amino acids of both the intact and the hydrolyzed pro-
tein is the same (15 gram).
protocol
Patients continued to take their antidiabetic medication after screening. They 
maintained their normal dietary and physical activity patterns throughout the 
entire experimental period, but refrained from heavy physical labour and exer-
cise training for at least 2 days before each study day. The enrolled patients 
participated on three study days in total with a wash-out periods of one week 
between two occasions. 
In the evening prior to each study day, the patients took a standardized meal 
with a total energy content of 2676 kJ. The macro-nutrient energy distribu-
tion was 55 energy % carbohydrate, 28 energy % fat, and 17 energy % protein. 
This was followed by an overnight fast of at least 12 hours. During study days, 
patients remained fasted and refrained from xanthine-containing products as 
long as measurements continued. Lunch was offered after completion of the 
last measurement. 
blood sampling and analysis
Blood samples were drawn by sampling from an intravenous cannula inserted 
into a forearm vein. Blood was collected at -5, 0, 10, 20, 30, 40, 50, 60, 90, 120, 
150, 180, 210 and 240 minutes after treatment ingestion for glucose, insulin and 
glucagon. Blood samples for insulin and glucose were collected in non-additive 
tubes. The samples were allowed to clot for 30-45 minutes and subsequently 
centrifuged at 4°C for 10 minutes at 2000 g. Samples were stored below -20°C 
until analysis. Blood samples for glucagon were collected in pre-chilled edta 
tubes. The samples were put on ice and within one minute 50 µl, 500 kie Trasylol 
(Bayer, Germany) was added, centrifuged at 4°C for 10 minutes at 2000 g and 
within 30 minutes after collecting stored at a minimum of -20°C until analysis. 
Glucose and insulin concentrations were measured in an automated assay 
using a fully automated Immulite analyzer (Immulite 2500 Analyzer Assay, 
euro/dpc, uk). Glucagon was measured using a radioimmunoassay (ria, 
Linco Research Inc., St Charles, mo, usa). The assays were performed at the 
Central Laboratories for Clinical Chemistry of lumc. All assays were validated 
to manufacturer standards prior to study sample analysis. All samples from the 
same subject were processed within the same batch. 
power calculation
As data from former studies did not yield enough information for a cross-over 
power calculation, a conservative power calculation with relatively high stan-
dard deviation and a power of 90% was conducted. This resulted in a necessary 
effect size of 21.7 mmol/L*4hrs , assuming a standard deviation of differences 
of 39.0, using a paired t-test with a 0.05 two-sided significance level for 36 
subjects.
statistical analysis
All data were entered into the analyses. Pharmacodynamic endpoints (post-
prandial serum glucose, insulin and glucagon levels) were analyzed separately 
by mixed model analysis of variance with treatment, occasion visit, time and 
treatment by time as fixed effects, with subject, subject by time and subject 
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by treatment as random effect (subjects received three of four possible treat-
ments), and with the (average) baseline value as covariate. Variables were 
analyzed after log transformation and least square means (lsm) estimates 
were calculated within the model. All data handling and statistics were per-
formed using sas for Windows version 9.1.2 (sas Institute, Inc, Cary, nc, usa).
results
subject characteristics 
Sixty subjects were screened for the study. Twenty-four subjects were excluded 
from participation because they did not meet the inclusion criteria. Thirty-six 
patients entered the study; 27 males and 9 females. Demographics of the 
patients are shown in Table 2. Eleven of 15 patients on monotherapy for t2dm 
used a biguanide drug. 
Twelve patients used a combination of a biguanide and sulfonylurea deriva-
tive, and six a biguanide and a thiazolidinedione drug. Three patients were on 
triple therapy. The majority of the patients received multi-modality treatment 
because of the increased cardiovascular risk associated with t2dm; 19 patients 
used statins, 23 antihypertensive medication and 10 patients received antico-
agulant or antiplatelet therapy. Occasional use of analgesics or antacids was 
also reported, but none of concomitantly used drugs were considered to inter-
fere with the objectives of the study (Table 3).
tolerability
No significant adverse events (ae) were recorded during this study. The most 
frequently occurring ae was gastrointestinal-related and consisted of abdomi-
nal cramps with or without diarrhea (n=7) or constipation (n=2) and nausea 
(n=1). The aes were mild, transient and did not need intervention. No signifi-
cant differences between treatments were found for the occurrence of aes. All 
36 subjects finished the study and attended all three occasions. 
hormones and glucose
The effect on average serum glucose concentration of insV treatment with or 
without added leucine was indistinguishable, and both interventions resulted 
in 4.7% lower glucose concentrations compared to placebo (p=0.0036, 95% 
ci: -7.7% to -1.6% for both, Figure 1, Table 4). 
There was no difference in postprandial glucose concentrations between 
placebo and the treatment with unhydrolysed protein (95%ci from -4.8% 
to 1.5%). The difference in effect on average serum glucose concentrations 
between the unhydrolysed protein and both insV treatments was 3%. Glucose 
declined to baseline at approximately 3 hours and was below baseline for the 
remainder of the observation period.
Average insulin concentrations increased rapidly after intake of all pro-
tein containing meal replacements (Figure 2). The strongest insulin increase 
compared to placebo occurred after insV with added leucine (Table 4: 51.8%; 
95% ci: 41.1 to 63.4%, expressed as estimate of the difference over the 4 
hour observation period). The increase in insulin after insV treatment without 
leucine (26.1%) was significantly less than the increase in insulin after unhy-
drolysed protein (36.0%).
Average glucagon attained peak concentrations at approximately 30 min-
utes and declined below baseline approximately 1 to 1.5 hours after treatment 
intake (Figure 3). The increase of glucagon after placebo was minimal. The 
increase in glucagon after the treatment with unhydrolysed protein and both 
insV treatments compared to placebo was similar and amounted to approxi-
mately 14% (95% ci: 7.5% to 20.2%, Figure 3).
discussion
Postprandial glucose concentration is increasingly seen as an important 
determinant for management of HbA1c concentrations [1;23]. A reduction 
in postprandial glucose of 0.8 mmol/L (about 10%) (due to diet and lifestyle 
intervention) is related to a reduction in t2dm incidence of 58% [24]. The dia-
betes prevention program research group showed that lifestyle intervention 
was significantly more effective than metformin (reduced incidence of 58% 
vs 31%) [25]. It is reasonable to assume that the combination of an energy-
balanced diet and protein hydrolysates may have clinical relevance in opposing 
the development of insulin resistance by attenuating the postprandial rise in 
blood glucose concentration. 
The aim of this study was to compare the effects of a single, low dose of 
hydrolysed protein, with or without added leucine, and of unhydrolysed 
protein on blood concentrations of glucose, insulin and glucagon in t2dm 
patients. The present data confirm results from earlier studies [12;15;19] that 
protein hydrolysates can lower postprandial glucose concentrations when 
taken along with a carbohydrate load. This study also shows that this effect 
is still present at much lower doses than employed previously. Many studies 
employed doses of around 0.3-0.4 g/kg hydrolysate [12;15;19;26] which is con-
siderably higher than the 15 g protein (approximately 0.2 g/kg body weight) 
used in the current study. Furthermore, the effect of the tested hydrolysate 
on postprandial glucose does not depend on its leucine content, since treat-
ment with either insV or insV+leu reduced postprandial glucose to a similar 
extend, even though insV+leu induced a larger insulin response. Both insV and 
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insV+leu outcompeted unhydrolysed protein in terms of glucose lowering. All 
three active treatments induced a relatively short lasting increase in glucagon 
concentrations. 
There is ample evidence that certain proteins, protein hydrolysates and 
amino acids stimulate the release of insulin. Indeed, consumption of a com-
bination of proteins and carbohydrates causes a more pronounced insulin 
response than ingestion of carbohydrates alone [7]. Previous research with 
insV in patients with t2dm has shown that co-ingestion of this product with 
carbohydrate augments the insulin response and enhances glucose disposal 
[12;15;19]. It should be noted that protein hydrolysate was administered on 
top of the carbohydrate shake that was provided in the placebo group, which 
induced a higher caloric load in the treatment groups. The fact that the hydro-
lysates lowered glycemic response even in the face of a higher caloric load 
further stresses the glucose lowering potential of the interventions.In this 
study the effect of additional leucine in hydrolysated casein was evaluated in 
view of contradictory previous findings [15;27]. The data indicate that this mix-
ture induced the largest increase in insulin concentrations (Figure 2). However, 
the postprandial glucose responses following treatment with insV+leu were 
similar to treatment with insV without additional leucine. These findings are in 
line with an earlier postprandial study [15] with the same product. It is unclear 
why insV+leu induced a greater insulin response, but no additional lowering 
of plasma glucose, compared to insV. Glucagon responses were measured to 
assess whether the glucose response to the leucine-induced insulin increase 
would be offset by increased glucagon concentrations. This appeared not to 
be the case, since the glucagon responses to insV and insV+leu were similar 
(Figure 3). 
insuvida™ versus unhydrolysed protein
insV tended to lower glycemic responses compared to intact casein and this is 
significant over the 0-2 hr period (estimated of the difference -4.3%; 95%ci: 
-1.1 to -7.4%, Figure 1). These data support the notion that for postprandial 
glucose management, the added value of a casein hydrolysate as compared to 
intact casein is especially pronounced in the early post-prandial phase. This is 
probably due to a difference in rate of appearance of amino acids in the periph-
eral circulation between whole casein protein and the casein hydrolysate [28]. 
Casein protein and their respective peptide hydrolysates were emptied from 
the stomach at similar rates, but the speed of intestinal amino acid absorp-
tion was slower for the casein protein solution. Although a minute amount 
of chromium (0.25 mg) was present in the insV treatments, it is unlikely that 
this contributed to the difference between the hydrolysate and the unhydro-
lysed protein as none of the well-designed studies have ever demonstrated any 
effect of chromium on (post-prandial) glucose regulation in humans [29, 30]. 
discrepancies; insulin and glucose effect 
In view of the size of the insulin response to protein-rich treatment, the post-
prandial glucose lowering effect is moderate [12]. It is well known that glucagon 
and insulin have opposite effects on (postprandial) glucose concentrations and 
are closely interlinked. Therefore, it is more important to consider the ratio of 
insulin to glucagon in evaluating a clinical situation rather than considering the 
concentrations of either hormone alone. 
Plasma glucagon concentrations peaked before a decrease in plasma glu-
cose occurred; respectively at 30 min and 60 min (Figure 1 and 3). Therefore, 
other factors than glucose concentrations must have been influencing this 
glucagon response. Proteins and amino acids stimulate both α- and ß cells 
in the pancreas, thus stimulating both the glucagon and the insulin release 
[9, 10, 31, 32]. Moreover, ß cells appear to be more responsive to protein than 
α cells [31]. It has been shown that glucagon release depends on the protein-
to-carbohydrate ratio of the meal [33-35]; a higher ratio is associated with an 
increased glucagon release. Calbet et al. found that the glucagon response to 
protein feeding was linearly related to the plasma amino acid concentration [9]. 
Thus, lower protein loads would be more appropriate to induce higher Insulin/
Glucagon (i/g) ratio, while by increasing the protein load mainly glucagon 
responses will be affected resulting in lower i/g ratios [31]. Therefore, it appears 
that the secretion of pancreatic glucagon during protein intake in association 
with insulin secretion, serves to limit the decline of glucose concentration. This 
may explain that hypoglycemia has never been observed in this or the previous 
studies with this hydrolysate.
A single dose of a casein hydrolysate with and without the addition of leu-
cine enhanced the carbohydrate-induced insulin response in t2dm patients, 
resulting in significantly lower plasma glucose concentrations compared to 
placebo and intact casein. In addition, the secretion of pancreatic glucagon 
was increased during all three active treatments associated with increased 
insulin secretion. This mechanism may have limited the decline of plasma glu-
cose concentrations and may be responsible for the absence of hypoglycemia. 
Further research is required to determine the long-term clinical benefit of a low 
dose of insuVida™, with and without additional leucine. 
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Protein: insuVida™ casein hydrolysate - - 17.61** 17.61**
Protein: Sodium caseinate (Saneigien) - 15.0 - -
L-leucine - - - 5.00
Maltodextrin: Maldex G 120 17.00 17.00 17.00 17.00
Dextrose monohydrate (Meritose 200) 18.47 18.47 18.47 18.47
Vegetable oil (rapeseed) 5.00 5.00 5.00 5.00
Additives (specified below) 8.94 8.94 8.94* 8.94*
Additives: Vitamin+Mineral premix: 2.85 gram, Gum (Xanthan and Guar) 0.48 and 0.12 gram, Sucralose 
0.036 gram, Flavour lemon 0.3 gram, Lecithin: 0.15 gram and * Chromium 0.00025 gram. ** Net protein 
weight: 15 gram.
table2 Subject demographics
Gender 9 Females / 27 Males
Age (yrs) 61.5 ± 5.1 
bmi (kg/m²) 28.1 ± 3.6 
Diagnosis of t2dm (yrs) 7 ± 5 
HbA1c (%)* 6.8 ± 0.9 
Fasting glucose (mmol/L) 9.6 ± 2.3 
Total cholesterol (mmol/L) 4.67 ± 1.02  
Triglycerides (mmol/L) 1.57 ± 0.70  
* HbA1c glycated hemoglobin 
table 3  Concomitant medication
Oral antidiabetics Monotreatment n=15
Dual treatment n=18
Triple treatment n= 3
Cardiovascular Lipid Lowering n=19
Blood pressure lowering n=23
Anticoagulant/antiplatelet n=10
Central nervous System Analgesic / Occasional sedative n=6
GI tract Antacid n=4
Endocrine Thyroid hormone n=2
Urogenital tract Prostate hypertrophy n=2
Pulmonary tract Anti-allergic n=1
Anti-asthma n=1
Miscellaneous Eye drops / vitamins / Acetylcysteine / Allopurinol n=5
table 4 Summary of profile analysis results
Estimate of the difference (%) of postprandial serum glucose levels. Insulin 
and glucagon levels from 0-4 hours after treatment ingestion with 95% 
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figure 1 lsms Serum glucose for each treatment
Dot: placebo, Triangle: unhydrolysed casein, Square: insV, Circle: insV+leucine. 
The figure represents the time course of the least square mean of serum 
glucose (with 95% ci error bars). Significant differences as compared with 
placebo are indicated for insV and insV+leucine (p<0.003).
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figure 2 lsms Insulin for each treatment
Dot: placebo, Triangle: unhydrolysed casein, Square: insV; Circle: insV + 
leucine. The figure represents the time course of the least square mean of 
insulin (with 95% ci error bars). Significant differences as compared with 
placebo are indicated for all three treatments (p<0.0001).
figure 3 lsms Glucagon for each treatment
Dot: placebo, Triangle: unhydrolysed casein, Square: insV, Circle: insV+leucine. 
The figure represents the time course of the least square mean of glucagon 
(with 95% ci error bars). Significant differences as compared with placebo are 
indicated for all three treatments (p<0.0001).
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background The aim of this study was to characterize a glucagon challenge 
test as a tool in diabetes research by assessing the inter- and intra-individual 
variability, and investigating the activity of the autonomic nervous system 
(ans) during the challenge, as this might have an indirect impact on glucose 
homeostasis. 
methods The study was performed in 24 healthy volunteers separated in 
two groups. The first group of 12 volunteers underwent a 5h glucagon chal-
lenge during a pancreatic clamp procedure with infusion of [6,6-²H²] glucose 
in combination with heart rate variability measurements. In the second group, 
12 other healthy volunteers underwent two 6h glucagon challenges separat-
ed by 6 weeks, and fat biopsies were taken for analysis of glucagon receptor 
expression.
results Serum glucose rose rapidly after glucagon infusion, and reached a 
plateau at 90 min. The time profiles suggested rapid development of tolerance 
for glucagon-induced hyperglycemia. During the glucagon challenge intra- 
and inter individual variabilities for hepatic glucose production, the rate of 
disappearance of glucose and plasma glucose were approximately 10-15% for 
all variables. Hyperglucagonemia did not affect heart rate variability. Human 
adipose tissue had a low, but variable, expression of glucagon receptor mrna.
conclusions This standardized glucagon challenge test has a good repro-
ducibility with only limited variability over 6 weeks. It is a robust tool to explore 
in detail the contribution of glucagon in normal and altered glucose homeosta-
sis and can also be used to evaluate the effects of drugs antagonizing glucagon 
action in humans without confounding changes in ans tone. 
introduction 
The who estimated that the number of people in the world suffering from dia-
betes by 2030 will have surpassed 360 million [1]. Especially the number of type 
2 diabetes mellitus (t2dm) patients is expected to rise exponentially [2]. t2dm 
is a characterized by chronic insulin resistance in liver and muscle, impaired 
insulin secretion in relation to insulin resistance and relative glucagon excess. 
In the absence of a defect in ß-cell function, individuals can compensate for 
insulin resistance with appropriate hyperinsulinemia. However, loss of ß-cell 
function ultimately leads to postprandial and fasting hyperglycemia that char-
acterizes t2dm. Current treatments focus on reduction of insulin resistance, 
on stimulation of insulin secretion and/or on insulin treatment. However, 
these treatments are not successful in restoring glucose metabolism in t2dm 
patients. Therefore, alternative targets are being investigated to improve glu-
cose homeostasis in t2dm. 
Glucagon could be such a target as elevated levels of circulating glucagon in 
t2dm patients results in increased hepatic glucose output, which contributes 
to (postprandial) hyperglycemia [3;4]. The glucagon receptor (gcgr) is mainly 
expressed in liver and in kidney with lesser amounts found in heart, adipose 
tissue, adrenal glands, pancreas, cerebral cortex and gastrointestinal tract [5]. 
Considering the role of hyperglucagonemia in the pathophysiology of t2dm, 
inhibition of gcgr action could represent an innovative target of therapeutic 
agents for t2dm [6], as attenuation of glucagon action in the liver reduces 
hepatic glucose output in experimental models and humans [7-9]. Hence, 
there is a need for reproducible tests that can be used to quantify the con-
tribution of glucagon on glucose homeostasis. Ideally, these tests should be 
suitable to be used in drug development aimed at interfering with gcgr action 
in humans.
Two variants of glucagon tests have been explored: bolus administration or 
infusion of glucagon [7;10]. Bolus administration of glucagon, which is most 
commonly used to treat insulin-induced hypoglycemia in diabetic patients, 
has the disadvantage that it only allows exploration of instantaneous effects. 
Furthermore, as bolus administration of glucagon is commonly performed 
without inhibition of the release of other (pancreatic) hormones affecting 
glucose homeostasis, it is not an optimal method to adequately assess the 
contribution of glucagon per se. The infusion variant with selective hyperglu-
cagonemia and concomitant, fixed insulin concentrations theoretically offers 
advantages, compared with the bolus test, but these advantages have not 
been exploited fully, because some important characteristics of this glucagon 
test variant have not been reported. We therefore investigated the inter- and 
intra-individual variability, the repeatability over a period of 6 weeks, and the 
effect of this test on the autonomic nervous system (ans). This time frame 
was chosen as most diabetes drugs are to be taken over a longer period and 
a 6-weeks period allows to characterize the sustainability of the mechanism 
of action as therapeutic effects are commonly at steady state at this period. 
Furthermore, we assessed the activity of the ans during the challenge, as this 
might have an indirect impact on glucose homeostasis [11;12]. 
Pre-clinical studies have shown that the glucagon receptor is expressed in 
mammalian adipose tissue [13]. When the glucagon receptor would also be 
expressed in human adipose tissue, it could be a direct biomarker of pharma-
cological activity in humans for drugs that act by reducing the amount of the 
receptor or modulation of the receptor because adipose tissue can be obtained 
easily in humans [14]. As a first step we performed human abdominal and dor-
sal fat tissue biopsies to investigate glucagon receptor mrna expression. 
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The study was performed in 24 healthy volunteers divided in two groups of 
12 subjects each. The first group of 12 subjects underwent a 5-hr glucagon 
challenge test in combination with heart rate variability measurements. In 
the second group, 12 other subjects underwent two 6-hr glucagon challenges 
separated by 6 weeks. Fat biopsies were taken for analysis of glucagon receptor 
expression in adipose tissue.
Healthy volunteers of both genders and aged between 18-65 years were 
included into the study after informed consent was obtained. Exclusion cri-
teria consisted of pregnancy or the intention to become pregnant; known or 
suspected addiction to alcohol or narcotics; positive test results for Hepatitis 
B, Hepatitis C or hiv; and any clinically significant abnormality in the routine 
physical exam (incl. bmi ≥ 30 kg/m²), hematology, biochemistry and urinaly-
sis. All experiments were approved by the institutional ethical commission 
and performed according to the principles of the International Conference on 
Harmonization, Good Clinical Practice and the Helsinki Declaration.
the hyperglucagonemic challenge during pancreatic 
clamp conditions
Subjects were required to continue their normal diet and activities. After an 
overnight fast of 10h, a catheter was inserted into an antecubital vein of each 
subject for infusion of the hormones used in the glucagon challenge. The 
challenge consisted of two phases: a run-in period of 3 hrs to achieve steady 
state conditions of glucose tracer/trace ratio’s, followed by a 3 hr pancreatic 
clamp. Glucose kinetics were assessed by administration of a priming bolus of 
5 mg.kg¯¹ followed by continuous iv infusion of 0.05 mg.kg¯¹.min¯¹ of [6,6-
²H²] glucose (Cambridge Isotope Laboratories, usa). The pancreatic clamp 
procedure consisted of simultaneous infusion during 3hrs of somatostatin 
at 0.1 µg.kg¯¹.min¯¹, glucagon at 3 ng.kg¯¹.min¯¹ and insulin at 4 mU.m¯².
min¯¹. Somatostatin was purchased from ucb Pharma (The Netherlands) 
and glucagon and insulin were purchased from Novo Nordisk Pharma (The 
Netherlands). A second catheter was inserted into a contralateral dorsal hand 
vein for blood sampling. The hand was placed in a heated-box (50°C) to arte-
rialize venous blood for labeled glucose sampling. Venous blood sample were 
drawn at regular intervals and were used for determination of (non-)labeled 
glucose, glucagon, insulin, C-peptide and growth hormone concentrations. 
Glucose, glucagon and insulin samples were collected every 15 min during 
the last hour of the enrichment episode and every 15 min during the glucagon 
infusion. Samples for C-peptide and gh were drawn every 30 minutes during 
the glucagon infusion. For subject safety frequent bedside glucose measure-
ments were made throughout the observation period using a glucometer 
(Glucocard x-meter gt-1910, Arkray Inc, Japan). 
heart rate variability
In the first 12 healthy volunteers, 5-min ecg-recordings were made in supine 
position using the CardioPerfect ecg recording system (Cardiocontrol, The 
Netherlands). Measurements were made 1 hr and immediately before the 
start of the challenge and 1 hr after the start of the challenge, with the lat-
ter time point coinciding with the period of maximal hyperglycemia. Subjects 
were instructed to remain calm and breath quietly, not allowed to speak and 
to fall asleep. ecg recordings were scrutinized for artefacts and subsequently 
analyzed for the time and frequency domain parameters with the software sup-
plied with the device according to the most recent guidelines [15]. The selected 
read-outs were the power in the low (lf) and high frequency (hf) domain and 
the ratio of the low over high frequency power (lf/hf).
adipose tissue biopsies
Fat biopsies were taken before the glucagon infusion test, as previously 
described [14]. In short, subcutaneous fat samples were taken of the dorsal 
gluteal area and the abdominal wall by suction after local infiltration with lido-
caine. Samples were handled under aseptic conditions, snap frozen in liquid 
nitrogen and subsequently stored at –80° C until analysis. 
laboratory analysis
Blood samples for insulin and C-peptide were collected in plain tubes and ana-
lyzed using standard validated immune-radio-metric assays (Biosource Europe 
S.A. Nivelles, Belgium; assay cv 5.9-7.9% for insulin, 2.9-5.4% for C-peptide). 
Glucagon samples were collected in plain tubes with aprotinin (Trasylol™, 
Bayer, 500 kie/50 µl) and analyzed using radioimmuno assay (Linco research, 
Missouri, usa; assay cv 4.3%). Blood samples for glucose and [6,6-²H²] glucose 
were analyzed using a validated gas chromatography with mass spectrometry 
as detection method as described previously [16]. Glucagon receptor expres-
sion in the fat biopsies was determined using a previously validated protocol for 
successful purification of mrna from adipose biopsy samples [14]. Glucagon 
receptor mrna expression in adipose tissue was quantified using a standard 
quantitative reverse transcription and polymerase chain reaction (qrt-pcr) as 
previously described for hepatocytes [17].
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Hepatic glucose production and rate of disappearance of glucose were calcu-
lated using the single pool non steady-state Steele’s equations (pool fraction: 
60%), as adapted for the use of stable isotopes [18]. Glucagon, insulin, hepatic 
glucose production, C-peptide, and growth hormone (gh) responses are 
presented as average responses over time. The inter- and intra-individual vari-
ability of the test was assessed using the area under the curves for glucagon, 
insulin, rates of appearance and disappearance of glucose, and plasma glucose 
concentrations during the glucagon infusion. Literature data suggests that 
glucagon receptor antagonism using small molecules, monoclonal antibodies 
or antisense approaches can reduce hgp in the order of 30-70% [7-9]. Based 
on our data and the literature data, power calculations were performed to cal-
culate the number of subjects that would be needed to detect a 40% difference 
in hepatic glucose production rate after a 6 wk treatment with 80% power at 
an alpha level of 0.05 using a 2-sided paired t-test. The time profile of the lf/hf 
ratio was compared after log-transformation using a mixed model of variance. 
Data are presented as mean and standard deviation unless otherwise indi-
cated. All analyses were performed using sas for Windows version 9.1.3 (sas 
Institute, Inc, Cary, nc, usa).
results
The first group of 12 subjects consisted of 4 females/8 males, age 32 ± 15 (18-
61) years, and bmi 24 ± 3 kg/m². The second group of 12 subjects consisted of 
male subjects, age 44 ± 20 (18-63) years, and bmi 24 ± 3 kg/m².
During the glucagon infusions, short-lasting, transient adverse events such 
as nausea, dizziness and headache of minor severity occurred as reported pre-
viously [19]. The fat biopsies were well tolerated and none of the participants 
rated the pain/discomfort higher than a vein puncture. During the glucagon 
challenge tests mean (±sd) growth hormone decreased from 6.7 (± 9.9) to 0.1 
(±0.07) mU/L and C-peptide decreased from 0.7 (±0.3) to 0.1 (±0.07) nmol/L, 
suggesting efficient blockade of endogenous (pancreatic) hormone release. 
The time profiles of the hormones and glucose were highly similar in both 
study groups. Therefore, a detailed description is given of results in the first 
group, except for the comparison between the first and second challenge.
Glucagon levels increased from 56 (±20) ng/L before the challenge to 123 
(±27) ng/L within 30 minutes after start of the infusion and remained more or 
less stable thereafter (Figure 1). Plasma glucose levels rapidly increased from 
5.4 (±0.6) mmol/L before the challenge to a maximum of 12.6 (±2.5) mmol/L 
at 2 hrs during challenge, after which it tended to decrease. Glucose rapidly 
returned to baseline after stopping the challenge. The glucose enrichment 
(tracer-to-tracee ratio) was 3.0 (±0.4) % before the challenge, declined to 2.5 ± 
0.3% between 90-150 min after the start of the glucagon infusion, and started 
to increase thereafter. Insulin concentrations during the challenge (10 mU/L) 
were slightly lower than baseline levels (13 mU/L) in the first group and at the 
same concentration during the entire observation period in the second group 
at the first and second study day (11 mU/L and 12 mU/L, respectively). 
The increase in plasma glucose levels was caused by increased hepatic 
glucose production (hgp, defined as rate of appearance), as the rate of dis-
appearance of glucose remained at a stable level during the entire challenge, 
and did not differ significantly from the rate of disappearance during the basal 
period. hgp increased rapidly after the start of the glucagon infusion from 1.00 
(±0.56) to 2.85 (±0.65) mmol/min, remained 2-fold higher than basal levels 
for the first 70 minutes of the glucagon infusion and subsequently showed 
a gradual decline until the end of the glucagon infusion period (1.49 ± 0.59 
mmol/min). Plotting the glucagon concentration vs. hgp suggests that toler-
ance occurs for the hgp as the increase in glucagon (or maintenance of high 
glucagon levels) increases the hgp not further (Figure 2). The translation of 
increased hgp into increased plasma glucose concentrations is characterized 
by a substantial delay (counter-clockwise hysteresis).
The repeat of glucagon test after 6 weeks in the second group of 12 subjects 
showed highly similar results compared to the first group of volunteers. The 
variability in hormone levels and effect measures was estimated by calculating 
the area on the curves for glucagon, insulin, rates of appearance and disap-
pearance of glucose, and plasma glucose concentrations (Table 1). There was 
limited inter-test variability of these parameters as also reflected in the highly 
similar time course of the hgp (Figure 3). Using these data it was calculated 
that a study with 8 participants would have 80% power to detect a 40% differ-
ence in hgp at a 2-sided alpha level of 0.05.
heart rate variability (hrv) 
There was no effect of hyperglucagonemia on heart rate. The heart rate before 
the challenge was 57 (±7) bpm and during the challenge, when the glucose 
level was more than 2-fold higher compared to baseline, the heart rate was 
55 (±8) bpm. Hyperglucagonemia did not affect any of the hrv parameters, 
including the lf/hf ratio (Table 2).
adipose tissue glucagon receptor mrna expression 
The quality of rna obtained from the tissue biopsy was good with sufficient rna 
from many of the biopsy samples and no signs of degradation. However, initial 
qrt-pcr analysis revealed that the expression of glucagon receptor in the puri-
fied rna of the human adipose tissue was extremely low and variable (data not 
shown).
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This study demonstrated that a doubling of plasma glucagon concentrations 
in the presence of constant insulin concentrations induced hyperglycemia 
throughout the entire challenge period with maximal plasma glucose concen-
trations of approximately 12.6 mmol/L at 2hrs, in accordance with previous 
studies [7;20]. Hyperglucagonemia increased plasma glucose levels by stimu-
lation of endogenous glucose production, whereas hyperglucagonemia did 
not affect the rate of glucose disappearance. The prompt increase in plasma 
glucose levels within the first 30 min of glucagon infusion was caused by an 
almost 3-fold increase in the rate of hepatic glucose production, most likely 
explained by stimulation of glycogenolysis [21]. We demonstrated that the 
inter- and intra-individual variability of this glucagon test variant is relatively 
low (10-15%). Literature data suggests that glucagon receptor antagonism 
using small molecules, monoclonal antibodies or antisense approaches can 
reduce hgp in the order of 30-70% [7-9]. We therefore performed a power cal-
culation assuming a 40% reduction and showed that repeat challenges can be 
performed with a low number of subjects to detect differences of this magni-
tude. It can thus be concluded that the test in the format that we employed is a 
robust pharmacodynamic tool with good reproducibility. 
Our observations suggest that the effect of glucagon on hgp shows fea-
tures of tolerance. This is not surprising as the gcgr belongs to the G-protein 
coupled (class B) receptor family for which development of tolerance is com-
mon. It has been described previously that continuous stimulation of gcgr by 
glucagon results in a diminished response over time, and that the response 
can be restored by increasing the dose of glucagon [22]. In an animal model it 
was demonstrated that gcgrs are internalized after 30 min of glucagon stimu-
lation [23], which is in line with the time course of the decay in hgp observed 
in our study. An additional explanation for the observed glucagon tolerance 
could be that glycogen stores become depleted in the liver. Thirdly, hypergly-
cemia might directly antagonize the stimulatory action of glucagon on the liver 
[24], also under our experimental conditions in which hyperglycemia-related 
hormonal responses were inhibited by somatostatin infusion [22]. It would 
be interesting to investigate if, and to what extent, tolerance to glucagon also 
occurs in patients with t2dm with elevated glucagon concentrations, and if 
differences exist between the effect of glucagon on glycogenolysis and gluco-
neogenesis. In addition, we found that the translation of increased hgp into 
plasma glucose levels is delayed. This finding warrants further investigation 
as this occurred while insulin concentrations were absolutely stable and the 
disappearance rates of glucose were also rather stable. It might be argued that 
the observations on glucose disposal are less reliable as it is well known that 
the outcome of Steele’s equation depends on assumptions for instance on vol-
ume of distribution. However, also the time course of the tracer/tracee ratio’s 
tended to increase slowly over time, suggesting that the delayed translation of 
hgp into plasma glucose is a ‘real’ phenomenon. It is tempting to hypothesize 
that during the challenge other mechanisms also play a role. These could be, 
among others, other hormones/incretins involved in the regulation of glucose 
homeostasis.
Liver, muscle and fat tissue play a major role in glucose metabolism. Glucose 
metabolism is tightly regulated by interaction of hormonal and nervous sig-
nals. Insulin and glucagon regulate glycemic levels both directly and indirectly 
by influencing sympathetic and parasympathetic branches of the autonomous 
nervous system [25]. Therefore, we also measured heart rate variability and 
assessed the effect of hyperglucagonemia and the ensuing hyperglycemia on 
the components of ans tone. However, we did not observe an effect on heart 
rate and heart rate variability during hyperglucagonemia in healthy subjects. 
This suggests that changes in autonomic nervous system tone do not contrib-
ute significantly to the effects of hyperglucagonemia.
In diabetic mice gcgr mrna is expressed in adipose tissue [17]. As far as 
we are aware, there are no reports on gcgr mrna expression in humans. We 
explored the expression of the gcgr in human adipose tissue, especially since 
this could be a direct biomarker of pharmacological activity of drugs that affect 
gcgr action. We found that the expression level of glucagon receptor mrna in 
human adipose tissue was extremely low. This discrepancy in mrna expression 
between humans and rodents might reflect a currently unknown physiological 
difference in adipose glucagon metabolism between humans and mice, and/
or reflect a consequence of the pathological condition of the diabetic mice. It 
may be interesting to investigate gcgr mrna expression in adipose tissue of 
patients with t2dm. However, at present gcgr mrna expression, at least in 
healthy humans, is not a feasible biomarker for estimation of the amount or 
function of the gcgr.
In conclusion, we demonstrated that the effects of continuous infusion of 
glucagon on glucose metabolism has low intra- and inter-individual variability 
and is highly reproducible. The test is a robust tool to further explore the con-
tribution of glucagon in normal and altered disease or drug-induced glucose 
homeostasis.
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table 1 Coefficients of variation for intra- and inter-individual variability 
(n=12) for hepatic glucose production, glucose disposal and plasma glucose 





Hepatic glucose production 10.7 15.4
Glucose disposal 10.6 16.4
Plasma glucose 12.5 9.7
The variability was calculated using the area under the curve for the period of the challenge. 
table 2 Median (range) of heart rate variability parameters in the frequency 
domain (n=12).
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figure 1 Time course of glucagon, plasma glucose, glucose enrichment, 
hepatic glucose production (rate of appearance) and glucose disposal (rate 
of disappearance) during the hyperglucagonemic challenge. The start of the 
challenge was at t=120 min and consisted of simultaneous infusion of soma-
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background Fasting and postprandial glucagon levels are increased in Type 
2 diabetes mellitus (t2dm), potentially contributing to inappropriate hepatic 
glucose production (hgp). We compared the glucagon response between 
healthy volunteers and t2dm patients, and investigated the effects of oral anti-
diabetic drugs on glucagon-induced hgp.
methods A hyperglucagonemic challenge was performed in two popula-
tions; 36 healthy volunteers (hv) underwent one challenge in the first study, 
and 22 t2dm patients underwent two challenges in a second randomized 
crossover study, once when continuing and once when discontinuing oral anti-
diabetic medication and receiving overnight insulin to achieve normoglycemia. 
results A glucagon challenge induced a comparable increase in glucagon 
levels in hv and t2dm subjects. The elevated glucagon levels resulted in a 
stronger increase in glucose levels in t2dm continuing medication and hv than 
in t2dm subjects on insulin (11.8, 10.1 and 9.3 mmol/L, respectively), which 
was associated with a stronger stimulation of hgp (1.96, 1.74, and 1.41 mmol/
min, respectively). The rate in decline that followed maximal hgp was faster for 
hv compared to t2dm patients, independent of therapy.
conclusions These results demonstrate that hv have a more pronounced 
increase in hgp upon glucagon infusion and a faster decline in hepatic glucose 
production than t2dm patients, and exogenous insulin suppresses glucagon-
induced hepatic glucose production. This suggests that mitigation of the 
effects of glucagon in t2dm might be a therapeutic option, by introducing 
insulin in an earlier stage of the disease and/or developing medication target-
ing the glucagon receptor. 
introduction
In healthy subjects, the postprandial rise in glucose levels is limited by a prompt 
decrease in glucagon and increase in insulin levels. In patients with Type 2 dia-
betes mellitus (t2dm), plasma glucagon levels are not suppressed normally in 
response to nutrient ingestion [1], in addition to blunting of the normal post-
prandial rise in insulin levels [2]. Postprandial plasma glucagon levels remain 
at, or above, the pre-prandial levels, despite postprandial hyperglycemia. This 
failure to suppress glucagon secretion results in a substantial impairment 
in glucose tolerance due to an inappropriate postprandial hepatic glucose 
release [3]. Obviously, glucagon levels should be considered relative to the 
prevailing levels of both glucose and insulin, because when a normal insulin 
profile is reproduced, lack of glucagon suppression has a much smaller effect 
on postprandial glucose metabolism [4-6]. Nevertheless, in t2dm, elevated 
postprandial glucagon levels are not suppressed sufficiently and contribute 
to hyperglycemia [3;7]. Given the increasing recognition of glucagon as a key 
factor in the pathogenesis of t2dm [8], it is conceivable that novel treatment 
modalities may emerge including treatments that mitigate glucagon-mediat-
ed hepatic glucose output (hgp). 
The glucagon challenge test (or hyperglucagonemic clamp test) can be 
used to assess the effect of glucagon on hepatic glucose production (hgp). This 
glucagon challenge test has been evaluated as a method to investigate glyco-
genolysis in healthy volunteers [9;10] and diabetic patients [11;12]. Recently, we 
reported on the inter- and intra-individual variability, and repeatability of the 
glucagon challenge in healthy volunteers, and on the effect of the test on the 
autonomic nervous system [10]. Direct comparison of the response to hyper-
glucagonemia between healthy volunteers and t2dm patients is lacking, and 
the effect of oral antidiabetic medication on the glucagon response in t2dm is 
unknown. Therefore, we assessed the response to hyperglucagonemia in t2dm 
patients, at the same conditions applied previously in healthy volunteers. The 
patients underwent the glucagon challenge two times: once after continua-
tion of oral antidiabetic drugs and once after withdrawal of oral medication for 
two weeks and replacement by an overnight insulin infusion before the chal-
lenge. The glucagon response between t2dm patients and healthy volunteers 




Glucagon challenge data for healthy volunteers were obtained from a clinical 
study performed at the Centre for Human Drug Research (chdr) in Leiden, pre-
ceding the clinical study in t2dm patients. Healthy volunteers between 18-65 
years were included after obtaining informed consent. Exclusion criteria con-
sisted of pregnancy or the intention to become pregnant, known or suspected 
addiction to alcohol or narcotics, positive test results for Hepatitis B, Hepatitis 
C or hiv, and any clinically significant abnormality in the routine physical exam 
(incl. bmi ≥ 30 kg/m²), hematology, biochemistry and urinalysis. 
t2dm patients
t2dm patients participated in a two-way randomized, cross-over study at 
chdr, with the study periods separated by at least one month. All patients 
used metformin (dose range: 500-3000 mg daily) and 12 patients used a 
sulfonylurea derivative (glimepiride: n=8; tolbutamide: n=3, glibenclamide: 
n=1). The patients had never been treated by insulin or other oral antidiabetic 
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agent(s), and were not taking any medication known to affect glucose metabo-
lism. Furthermore, patients were free of any clinical evidence of cardiovascular, 
pulmonary, renal, hepatic, or other major organ system disease as determined 
by history, physical examination, and routine laboratory tests. In one period 
the subjects continued their oral antidiabetic drugs and in the other period the 
oral antidiabetics were discontinued for 2 weeks before the challenge. During 
the latter period, the study day was preceded by an overnight insulin infusion 
to achieve normoglycemia before the start of the challenge. During the wash-
out period, patients reported to the clinical research unit after 1 week for a 
check including measurement of fasting plasma glucose (fpg) levels. When 
fpg was > 15 mmol/L during the wash-out period, patients were withdrawn 
from further participation. Immediately before start of the glucagon chal-
lenge, capillary blood glucose was measured as well; if fpg was >12 mmol/L, 
the glucagon challenge was cancelled. Furthermore, frequent bedside glucose 
measurements were performed throughout the clinical study period using a 
glucometer (Glucocard x-meter gt-1910, Arkray Inc, Japan). 
The study protocol was approved by the ethics committee of Leiden 
University and performed according the Dutch Law on Medical Research.
the hyperglucagonemic clamp test
Subjects were required to continue their normal diet and activities. After an 
overnight fast, the hyperglucagonemic clamp test was performed, consisting 
of two phases: a run-in period of 3 hrs to achieve stable glucose isotope enrich-
ment, and a 3 hr pancreatic clamp study (Figure 1). After a priming dose of 5 
mg.kg¯¹ iv, [6,6-²H²] glucose was infused continuously throughout the study 
at a rate of 0.05 mg.kg¯¹.min¯¹ (Cambridge Isotope Laboratories, ma, usa). The 
pancreatic clamp study consisted of a simultaneous 3hrs infusion of soma-
tostatin (0.1 µg.kg¯¹.min¯¹; ucb, The Netherlands), glucagon (3 ng/kg/min; 
Novo Nordisk, The Netherlands), and insulin (4 mU.m¯².min¯¹; Novo Nordisk, 
The Netherlands). A second catheter was inserted into a contra-lateral dorsal 
hand vein for blood sampling. The hand was placed in a heated-box (50°C) to 
arterialize venous blood for labeled glucose sampling. Venous blood samples 
were drawn to determine (non-) labeled glucose, glucagon, insulin, C-peptide 
and growth hormone concentrations. Samples for isotope analyses, glucose, 
glucagon and insulin were collected every 15 minutes from 30 minutes before 
the start of the challenge until the end of the glucagon challenge (t=6 hour). 
Samples for C-peptide and gh concentrations were drawn before, during 
and at the end of the glucagon infusion period. The procedures did not differ 
between healthy subjects and t2dm patients with the exception that when 
oral treatment was discontinued in t2dm patients, subjects received an over-
night insulin infusion before the glucagon challenge to ensure fasting plasma 
glucose levels between 4.5 and 6.5 mmol/L before start of the challenge. This 
insulin infusion rate was continued during the glucagon challenge, in addition 
to the standard 4 mU.m¯².min¯¹ insulin during the pancreatic clamp. 
laboratory analysis
Blood samples for insulin and C-peptide were collected in plain tubes and 
analyzed using standard validated immune-radio-metric assays (Biosource 
Europe S.A., Belgium; assay cv 5.9-7.9% for insulin, 2.9-5.4% for C-peptide). 
Glucagon samples were collected in plain tubes with aprotinin (Trasylol™ (500 
kie/50 µl) Bayer, The Netherlands) and analyzed using a radioimmuno assay 
(Linco research, Missouri, usa; assay cv 4.3%). Blood samples for glucose and 
[6,6-²H²] glucose were analyzed using a validated gas chromatography with 
mass spectrometry as detection method as described previously [13]. All sam-
ples were analyzed in batches to reduce assay variability.
statistics
The healthy volunteer study and the t2dm study were designed and conducted 
as two separate studies. The study in t2dm patients was designed to have 80% 
power to detect a difference in means of glucose auc/time of 1.3 mmol with 
a 2-sided paired t-test and p<0.05 in a population of 16 patients. The hepatic 
glucose production and rate of disappearance of glucose were calculated using 
the Steele equations for non-steady state conditions as adapted for the use 
of stable isotopes [14]. The glucagon response between t2dm patients and 
healthy volunteers was compared, and the effect of oral antidiabetic drugs 
on the glucagon response was explored in the t2dm patients. Contrasts were 
analyzed using a mixed model analysis of variance (anova). Insulin was the 
only parameter that was log transformed. Estimated differences are presented 
for the overall time profile during the challenge, between 180 and 360 minutes 
and corrected for pre-values, unless otherwise stated. All analyses were 
performed using sas for Windows version 9.1.2 (sas Institute, Inc., Cary, nc, 
usa).
results 
Thirty-six healthy volunteers underwent a glucagon challenge; demographic 
data are presented in Table 1. Short-lasting, transient adverse events such 
as nausea, dizziness and headache of minor severity occurred during the 
glucagon infusions. During the glucagon infusions, headache (10 out of 36 
subjects, 28%), nausea (5 out of 36 subjects, 14%) and dizziness (5 out of 36 
subjects, 14%) were the most common aes. In the patient study, twenty-two 
t2dm patients on oral antidiabetic drugs were included; demographic data 
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are presented in Table 1. All patients used metformin (500-3000 mg daily), 12 
subjects in combination with a sulfonylurea derivative (8 subjects glimepiride, 
3 subjects tolbutamide, 1 subject glibenclamide). Within the population of 
t2dm patients, 12 subjects (59%) used statins, and blood pressure lowering 
agents were used by 6 patients (27%). None of the patients used drugs that 
have a known or suspected effect on glucose homeostasis such as ß-blockers 
or diuretics. All concomitant medication was continued throughout the study.
Fifteen of the 22 subjects underwent both clamps (68%), the baseline char-
acteristics were comparable. In seven patients a second challenge was not 
performed because of nausea and vomiting during the first challenge (n=5), or 
because glucose levels exceeded 15 mmol/L after one week without oral anti-
diabetic medication (n=2). During the glucagon infusions, headache (9 out of 
22 subjects, 41%), nausea (9 out of 22 subjects, 41%) and vomiting (4 out of 22 
subjects, 18%) were the most common aes. After stopping the challenge these 
symptoms resolved spontaneously within 5 minutes and without sequelae.
Before the start of the hyperglucagonemic challenge, plasma glucagon 
levels were well comparable between healthy volunteers and t2dm patients 
continuing oral medication, but lower in patients discontinuing oral medica-
tion and receiving overnight insulin (Table 2 and Figure 2A). After start of the 
hormone clamp (at t=180 min), glucagon levels increased to approximately 
125-145 ng/L within 30-60 minutes in all three studied groups. This plateau in 
glucagon concentration was maintained during the entire clamp without sig-
nificant differences between populations or between both study periods for the 
t2dm patients (Figrue 2A). During the glucagon challenge tests, endogenous 
release of glucagon and insulin was completely inhibited by somatostatin, as 
demonstrated by suppression of C-peptide levels (from 0.7 ±0.3 to 0.1 ±0.04 
nmol/L for t2dm on oral medication, and from 0.26 ±0.18 to 0.07 ±0.02 
nmol/L for t2dm receiving additional insulin).
Before start of the glucagon challenge, insulin concentrations were 10.1 
mU/L in healthy volunteers and 11.8 mU/L in t2dm patients on oral medica-
tion (reflecting endogenous insulin levels), and 2-fold higher when patients 
received insulin (reflecting endogenous insulin levels plus additional exog-
enous insulin to ensure normal fasting plasma glucose levels before start of 
the challenge, Figure 2B). During the challenge, plasma insulin concentra-
tions remained stable in all groups with an average of 10.6 mU/L in healthy 
volunteers, 9.2 mU/L in patients on oral medication, and 19.2 mU/L in patients 
treated with insulin (Table 2). 
Plasma glucose levels were stable before the start of the glucagon chal-
lenge, but lower when t2dm patients were studied after receiving overnight 
insulin (Figure 2C). Plasma glucose levels increased during the glucagon 
challenge to maximal values of 13.5 ±1.9 mmol/L at the end of the challenge 
when the patients used oral antidiabetics. During the challenge that was per-
formed after the overnight insulin, maximal glucose levels increased to 9.8 
±3.3 mmol/L. These levels were reached earlier; at 2 hrs after start of the chal-
lenge. The healthy volunteers had lower baseline glucose levels compared to 
t2dm patients in both study periods. The glucagon challenge induced a rise in 
glucose level to a maximal concentration of 11.5 ±1.7 mmol/L in healthy volun-
teers, which is lower than the patients continuing their standard medication, 
but higher than the patients receiving overnight insulin.
The increase in plasma glucose levels is explained by an increased hgp 
(defined as rate of appearance), since the rate of glucose disappearance 
remained fairly stable during the entire challenge in healthy volunteers and 
t2dm patients under both conditions (data not shown). hgp increased rapidly 
after start of the glucagon infusion. hgp increased approximately 142% (from 
1.2 ±0.3 to 2.8 ±0.6 mmol/min) in t2dm patients continuing oral antidiabetic 
drugs, while about the same increase of 149% (from 0.9 ±0.2 to 2.2 ±0.7 mmol/
min) was observed when patients received additional insulin (Figure 2D). The 
increase in hgp in healthy subjects exceeded the rise in t2dm patients, irre-
spective of the study condition, and amounted to 195% (from 0.9 ±0.2 mmol/
min to 2.8 ±1.0 mmol/min) at 25 minutes after challenge start. The rapid rise in 
hgp was followed by a gradual decline in all three study groups. Although, the 
rate of hgp decline appeared equal for the t2dm patients in both conditions 
studied (Figure 2D), hgp level returned to baseline in patients receiving addi-
tional insulin before the end of the glucagon challenge, but was still elevated 
compared to baseline in patients continuing oral antidiabetic drugs. The rate 
in hgp decline was faster for healthy volunteers compared to t2dm patients, 
reaching baseline hgp levels at the end of the glucagon challenge.
discussion
There is accumulating evidence that increased glucagon levels and glucagon 
action play an important role in the pathophysiology of t2dm. We performed 
glucagon challenges in t2dm patients to compare the hyperglucagonemic 
response between patients and healthy volunteers, and to assess the effects of 
commonly prescribed oral antidiabetic drugs (metformin and sulfonylurea) on 
glucagon-mediated stimulation of endogenous glucose production. We dem-
onstrated that the initial response to glucagon was stronger in healthy subjects 
and in diabetic patients on oral medication than in patients on insulin treat-
ment. The gradual decline in hgp following the initial peak markedly differed 
between t2dm patients and healthy volunteers. The decline in hgp, with an 
onset already early during the glucagon challenge, was faster in healthy volun-
teers than in t2dm patients, irrespective of antidiabetic treatment. The exact 
mechanism for this difference between populations is unknown, but since the 
decline in hgp is explained by the induction of glucagon tolerance [15;16], the 
explanation is likely related to that phenomenon.
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The rise in hgp following the glucagon challenge resulted in increased glucose 
levels. The glucose response to hyperglucagonemia in healthy volunteers was 
not markedly different from the glucose response in t2dm patients on oral 
antidiabetics, at least not when taking into account the difference in baseline 
glucose levels between both groups. This is in line with the observed initial 
increase in hgp upon hyperglucagonemia in both study groups, which was 
larger than the rise in hgp in diabetic subjects receiving additional insulin to 
control glucose levels. The maximal glucose response to a hyperglucagonemic 
challenge appears to be primarily driven by this initial rise in hgp. Differences 
between healthy volunteers and t2dm patients in subsequent hgp decline do 
not readily explain the glucose response.
Since the acute stimulatory effect of glucagon on hgp mainly reflects glyco-
genolysis [17], our data confirm that insulin directly inhibits the glycogenolytic 
response to hyperglucagonemia [18]. This explanation of a direct inhibition by 
insulin is also supported by our finding that the glucose disappearance rate 
was stable during the challenge. Obviously, indirect insulin effects such as the 
inhibition of lipolysis and proteolysis resulting in decreased release of gluco-
neogenic precursors or altered neural stimulation of the liver [19], or direct 
effects of glucose, may have contributed to a certain extent to the observed 
responses.
Our data suggest that mitigation of the effects of glucagon in t2dm might 
be a therapeutic option, since in t2dm the increase in hgp that follows upon 
glucagon stimulation is longer-lasting than in healthy volunteers. An antiglu-
cagon-based therapy could have a beneficial effect on elevated glucose levels 
as add-on therapy for insulin-based therapies, especially to limit the glycemic 
effects of elevated postprandial plasma glucagon levels as observed in t2dm 
[3]. However, it should be stressed that physiological interpretation of the col-
lected data is not straightforward. It should be taken into consideration that 
baseline glucagon levels were lower in patients received overnight insulin than 
in healthy volunteers or patients continuing their oral antidiabetic medication. 
This discrepancy was inevitable since it was aimed to reach comparable nor-
moglycemic levels (i.e. between 4.5 and 6.5 mmol/L) preceding the glucagon 
challenge in both conditions, and to prevent symptomatic hyperglycemia dur-
ing the challenge. We suggest that the most valuable exploration of the current 
data sets would require the development of an integrated glucagon-insulin-
glucose biometrical model. Such a model would allow a more sophisticated 
assessment of the relationship between observed effects, and offer insight into 
the potential effects of (pharmacological) modulation of one or more compo-
nents of the integrated model.
Although it is tempting to regard the hyperglucagonemic challenge as a 
relatively mildly burdening and safe methodological tool in clinical research, it 
is important to note that hyperglucagonemia is associated with short-lasting, 
transient adverse events such as nausea, vomiting, dizziness and headache 
[20]. It is remarkable that these events are not reported in literature [11;12]. In 
our experience, these effects were minimal in healthy subjects, but inciden-
tally so severe in t2dm patients that procedures had to be interrupted. In the 
present study, the events were equally divided over study periods and appeared 
to be unrelated to glucose levels. As methodological tool in t2dm patients, an 
alternative glucagon challenge should be considered at a more physiological 
glucagon dose. Rational adaptations of the test procedure would be to gradu-
ally administer glucagon, or to limit the duration of hyperglucagonemia.
In conclusion, our results demonstrate that the response to a hyperglu-
cagonemic challenge markedly differs between t2dm patients and healthy 
volunteers. Healthy volunteers show a greater increase in hgp upon glucagon 
infusion and also a faster decline in hepatic glucose production than t2dm 
patients, and exogenous insulin suppresses the glucagon-induced hepatic 
glucose production. This suggests that mitigation of the effects of glucagon in 
t2dm might be a therapeutic option, by introducing insulin in an earlier stage 
of the disease and/or developing medication targeting the glucagon receptor. 
Further research is needed to elucidate the potential role of glucagon antago-
nists as a therapeutic agent in t2dm. 
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table 1 Baseline characteristics healthy volunteers and t2dm patients.
 Healthy (n=36)  
(± sd; min-max)
t2dm (n=22)  
avg ± sd (min-max)
 Age (yrs) 40.5 ±18.3; (18-64) 56.0 ± 8.7 (29-65)
Gender 36 M 18M / 4F
bmi (kg/m²) 24.0 ±3.1; (17.6-29.9) 26.8 ± 3.2 (22.8-33.5)
Fasting glucose (mmol/L)  5.1 ±0.4; (4.2-5.7) 6.4 ± 1.8 (4.0-10.7)
HbA1c (%) 5.2 ±0.3; (4.6-5.7) 6.4 ± 0.6 (5.2-7.8)
Hip circumference (cm) 92.7 ±6.9; (82-109) 98.6 ± 5.3 (89.1-111)
Waist circumference (cm) 88.0 ±10.5; (70-111) 94.5 ± 8.8 (81-116)
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table 2 Statistical analysis results of glucagon, insulin, plasma glucose, 
hepatic glucose production (hgp) and rate of disappearance (Rd) before and 
during challenge without correction for pre-value. Presented is the 95% 
confidence interval of the treatment difference.
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t2dm-oral: Continuation of oral therapy 
t2dm-insulin: during insulin therapy (discontinuation of oral therapy)
figure 1 Glucagon challenge: infusion of labeled glucose, somatostatin, 
insulin and glucagon.
Basal period       Hyperglucagonaemic period
0 min  – – – 5 min 5 min  – – – 180 min 180min – – – 360 min 
[6.6'–2H2] glucose  
bolus 5 mg.kg¯¹
[6.6'–2H2] glucose  continuous 0.05 mg.kg¯¹ .min¯¹  
Somatostatin 0.1 μg.kg¯¹.min¯¹ 
Glucagon 3 ng.kg¯¹.min¯¹ 
Insulin 4 mU.m¯².min¯¹ 
* Patients discontinuing oral medication received an overnight insulin infusion before the glucagon challenge, 
see Methods. This insulin infusion rate was continued on top of the standard 4 mU.m¯².min¯¹ insulin during the 
pancreatic clamp.
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figure 2 Glucagon (a), insulin (b), plasma glucose (c), and hgp (d) in healthy 
volunteers and t2dm patients; averages with sd error bars (t2dm only).
Closed circles: continuation of oral medication. Open circles: insulin therapy 
(discontinuation of oral therapy). Triangles: healthy volunteers.
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chapter 5 
First proof of pharmacology 
in humans of a novel 
glucagon receptor  
antisense drug 
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background Fasting and postprandial hyperglucagonemia in type 2 diabe-
tes mellitus (t2dm) patients cause excessive hepatic glucose production (hgp), 
suggesting that attenuation of hepatic glucagon action could be a therapeutic 
strategy for t2dm. 
methods In this study we evaluated the safety, tolerability, pharmacokinet-
ics and pharmacodynamics in healthy human volunteers of single and multiple 
doses (50 to 400 mg) isis 325568, a 2́ -0-moe antisense (aso) developed to 
reduce hepatic glucagon receptor (gcgr) mrna expression. In the multiple 
dose cohorts, treatment consisted of 8 doses of isis 325568 or placebo over 
6-weeks. Drug effects were assessed using serial fasting glucagon measure-
ments and the glycemic response to a glucagon challenge at baseline and at 
the end of 6-week treatment. 
results isis 325568 was not associated with clinically relevant changes. 
Dose-dependent predominantly mild injection site reactions were the most 
common side-effect. Active treatment caused a gradual increase in fasting 
glucagon levels and, compared to placebo, a significantly blunted glucagon-
induced increase in plasma glucose auc (24%, p<0.0001) and hgp (13%, 
p=0.007) at the 400 mg/week dose. 
conclusion Six weeks treatment with isis 325568 in healthy volunteers 
attenuated glucagon-stimulated hgp and glucose excursions, supporting fur-
ther evaluation of the gcgr antisense approach in patients with t2dm.
introduction
Currently available drug therapy for patients with type 2 diabetes mellitus 
(t2dm) including the use of insulin is not completely successful in restoring gly-
cemic control. Thus, there remains a need for agents with novel mechanism(s) 
of action. A possibly feasible approach could be to ameliorate excessive hepat-
ic glucose production. This may be achieved by attenuating glucagon action as 
it has been shown that in t2dm the glucagon-insulin ratio is disrupted [1] and 
increased glucagon action is largely responsible for hallmark features of t2dm 
such as hepatic insulin resistance and increased rates of glucose production 
[2]. This suggests that targeting glucagon action is a distinct mechanism that 
may offer therapeutic possibilities (as add-on therapy) for t2dm patients cur-
rently uncontrolled with oral anti-diabetic agents. The effect of glucagon are 
mediated by binding to and activating the glucagon receptor (gcgr), which is 
mainly expressed in the liver and kidney, with lower expression levels in car-
diac, adipose and other tissues [3;4]. Pharmacological antagonism of glucagon 
action has been investigated non-clinically as a potential therapeutic approach 
for t2dm. Both peptide antagonists and monoclonal antibodies against gcgr 
attenuate hyperglycemia in animal models [5;6]. In addition, antagonism of 
the gcgr in humans suggests that the concept may be worthwhile to pursue 
[7], but issues relating to pharmacokinetics, selectivity, cross species differ-
ences and lack of sustained effects after non-competitive blockade have thus 
far hindered the development of clinically applicable therapies [8]. An alter-
native approach could be to use specific antisense oligonucleotides (asos) to 
the gcgr. isis 325568 is such an aso targeting gcgr mrna and was designed 
to function through an rnase h-dependent antisense mechanism [9]. rnase 
h efficiently induces antisense-mediated cleavage of mrna and is present in 
most mammalian cells. Antisense-mediated reduction of target mrna levels 
by this mechanism results in subsequent reduction in target protein levels [10]. 
Pharmacology studies with antisense drugs with dedicated (physicochemical) 
properties have shown that it is possible to achieve tissue-selective inhibition. 
This was also shown for species-specific gcgr antisense drugs including isis 
325568. It is possible to achieve selective inhibition of hepatic and adipose 
tissue gcgr expression, resulting in normalization of blood glucose levels 
in diabetic animal models without development of hypoglycemia [11;12]. In 
addition, gcgr antisense therapy increased levels of active glp-1 levels and 
improved pancreatic ß-cell function [12]. This suggests that specific liver- and 
fat-directed gcgr antisense therapy could offer a novel therapeutic approach 
in t2dm. Therefore, a study was performed for the first time in human subjects 
to evaluate the effects of the specific gcgr antisense drug isis 325568 with the 
aim to obtain proof of pharmacology in humans while also assessing its toler-
ability and pharmacokinetics.
methods
The study was conducted according to the principles of the Declaration of 
Helsinki, the Guideline for Good Clinical Practice, and the pertaining Dutch law. 
The study protocol was approved by the Central Committee on Research involv-
ing Human Subjects of the Netherlands. All subjects gave written informed 
consent before any study-related procedure was performed. 
experimental drug – isis 325568
isis 325568 is the 19 sodium salt of a 3́ → 5́  phosphorothioate oligonu-
cleo tide 20-mer in which each of the 19 internucleotide linkages is an 
o- o-l inked phosphorothioate diester. There are two 2́ -o-(2-methoxyethyl) 
(moe) modified ribonucleosides at the 3́  and 5́  termini flanking sixteen 2́ -de- 
oxyribonucleosides. The sequence of isis 325568 is 5́ - gMecaMectttgtggtgMe 
cMecaaggMec- 3́  where the underlined bases are 2́ -o-moe riboses and the 
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cytosine nucleotides are methylated. As such, it is a second-generation anti-
sense phosphorothioate oligonucleotide. In cynomolgus monkeys, which 
show almost 100% gcgr receptor homology at the isis 325568 binding site, 
isis 325568 was broadly distributed after subcutaneous (sc) injection, mainly 
to kidney and liver. Full-length isis 325568 is cleared from monkey tissues with 
a half-life of approximately 11 days in kidney and 13 days in liver. In 13-week 
mouse and monkey studies, aso dose-dependently reduced liver gcgr mrna 
expression to a maximum of 75-90% and resulted in 4- to 6-fold increases 
over baseline in plasma glucagon and active glp-1 levels. Despite the substan-
tial inhibition of gcgr expression, decreases in serum glucose levels below 
normal were not observed. Apart from the well described common systemic 
toxicities and side effects (for example, local inflammation resulting in injec-
tion site reactions) noted for this generation of asos at doses and exposures 
that exceed the intended clinical dose level and regimen no adverse findings 
were noted ([13] and data on file). Importantly, no alterations in renal function 
were observed in monkeys treated with 60 mg/kg/week. 
study population
The study was performed in 58 male volunteers who were considered healthy 
after medical screening. The subjects were between 18 and 65 years of age with 
a body mass index (bmi) below 30 kg/m², a fasting plasma glucose concentra-
tion below 6.4 mmol/L and Hb1Ac below 6.3%. Main exclusion criteria were 
clinically significant abnormalities in medical history or physical examination, 
and abnormalities on laboratory examination.
procedures
The study consisted of two parts. In the first part single sc doses of isis 325568 
were administered to 16 volunteers using a double blind design. The doses 
were 50, 100, 200 and 400 mg with a randomization ratio active:placebo of 
3:1. The 50, 100 and 200 mg doses were given as a single sc injection in the 
abdominal region, and the 400 mg dose was administered as 2 sc injections 
(200 mg each; one abdominal and one upper arm). Twelve samples for drug 
assay were taken from the time just prior to injection to approximately 72 
hours after injection for pharmacokinetic assessment of the drug. A 24-hour 
urine sample was also collected from each subject. Also, measurements of 
vital signs, ecg-parameters, routine laboratory, coagulation and complement 
factors were performed, and adverse events were recorded. A final follow-up 
assessment took place at approximately 30 days after dosing. 
In the second part of the study 4 sequential cohorts were given 8 doses of study 
drug over 6 weeks. The doses administered were 50, 100, 200 and 400 mg with a 
randomization ratio active:placebo of 3:1 for the 50 mg cohort (4 subjects) and 2:1 
in the other cohorts (12 subjects in each cohort). In all cohorts, samples for fast-
ing glucagon levels were taken before treatment up to 6 weeks after study drug 
administration. One week before dosing initiations, subjects in 100, 200 and 400 
mg dose cohorts underwent a pre-treatment glucagon challenge. The glucagon 
challenge was performed as previously described [7;14]. The procedure started 
with a run-in infusion with [6,6-²H²] glucose (Cambridge Isotope Laboratories, 
ma, usa), consisting of a priming dose of 5 mg.kg¯¹ and a 3 hrs continuous infu-
sion of 0.05 mg.kg¯¹.min¯¹. Subsequently, simultaneous infusions of glucagon 
(3 ng.kg¯¹.min¯¹), somatostatin (0.1 µg.kg¯¹.min¯¹) and insulin (4 mU.m¯².
min¯¹) were given for 3 hrs, while the infusion of [6,6-²H²] glucose was contin-
ued. Samples for (labeled) glucose, insulin and glucagon were taken regularly. 
One week later, the subjects were admitted to the clinical center and study 
drug was given on day 1, 3, and 5 by one hour iv infusions. Thereafter, the sub-
jects received the subsequent 5 sc doses at weekly intervals starting 3 days 
after the final iv dose. The site of injection alternated between the abdomen 
and upper arm. One week after the final sc dose a second glucagon challenge 
was administered. Thereafter, follow-up assessments were done for 9 weeks. 
Physical examinations, measurement of vital signs, collection of blood speci-
mens for clinical chemistry, hematology, coagulation, and complement tests, 
collection of urine for urinalysis, ecg measurement, and collection of blood 
and urine for drug assay were performed regularly throughout the trial. Full 
plasma pharmacokinetic profiles were obtained following the first intravenous 
infusion and following the final sc injection. Additional plasma samples were 
collected to measure trough and peak levels of the subsequent iv infusions. 
Samples for drug assay were taken just prior to the first, third, fifth and final sc 
dose. Twenty-four hour urine samples for drug assay were collected following 
the first and last dose.
drug assay
Plasma samples were assayed for isis 325568 using a validated hybridization 
elisa [15]. The analysis quantifies the parent compound in plasma with <6% 
cross-reactivity to oligonucleotide with one base removed (19mer), and no 
cross-reactivity to the n-2 metabolites of isis 325568 (18mer) and endonucle-
ase shortened oligonucleotides. The calibration range of the assay was 0.5 to 50 
ng/mL for isis 325568, with the low end defining the lower limit of quantitation. 
Urine samples were analyzed after a 2-step solid phase extraction. Analysis 
was accomplished by capillary gel electrophoresis (cge) with uv detection 
(260 nm) using a method similar to that previously reported [16]. The linear 
quantification range was from 0.2 to 20.0 µg/mL, with the lower limit repre-
senting the lower limit for quantitation. Metabolite concentrations and total 
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oligonucleotide concentrations were quantified using calibrators and normal-
ized to the relative extinction coefficients of the putative metabolites and that 
of the parent compound. 
laboratory tests
Samples for routine clinical chemistry, hematology, and coagulation were 
analyzed using routine methodology. Insulin was measured with an immu-
noradiometric assay (Biosource Europe s.a.; interassay coefficient of variation: 
6.1-6.5 %), glucagon was measured with a radioimmunoassay Kit (linco 
research, Missouri, usa; cv 7.3-13.5 %), and active glp-1 was measured using 
the Meso Scale Discovery assay by Pacific Biometrics Inc (Seattle, Washington, 
usa). The assays were performed in batches to reduce assay variability. 
Glucose, labeled [6,6-²H²] glucose concentrations and tracer/tracee ratios 
were measured using a validated gc/ms assay at the laboratory for endocrinol-
ogy laboratory of lumc [17].
For exploratory purposes, ifnα, il-6, mcp-1, and mip-1α were measured with 
elisa kits that are validated for in vitro diagnostic use, but had low detection 
limits and reasonable variability. Complement C5a was measured using human 
C5a elisa kits (HyCult Biotechnology, Uden, The Netherlands).The placebo and 
pre-dose data of all subjects in this study showed a mean (sd) C5a concentra-
tion of 267 (437) ng/mL. Factor Bb was measured using quidel Bb Plus Enzyme 
Immunoassay Kit (quidel, San Diego, ca, usa). The placebo and pre-dose data 
of all subjects in this study showed a mean (sd) Bb value of 0.88 (0.22) µg/mL.
statistical analysis
The safety and tolerability data analysis was performed on all subjects that 
were dosed and was descriptive. Pharmacokinetic parameters were obtained 
from plasma isis 325568 concentration-time profiles following single sc injec-
tion (first study part), single dose 1-hr iv infusion (first dose second part) and the 
final sc injection (last dose second part of the study). In addition, urinary excre-
tion of isis 325568 and its oligonucleotide metabolites were measured in 0-24 
hr collections following both single and multiple dose administration. Plasma 
pharmacokinetics for isis 325568 were analyzed using a non-compartmental 
method with WinNonLin Professional Version 5.01 software (Pharsight Corp., 
Mountain View, ca), and included peak plasma concentration (Cmax), time to 
reach peak plasma concentration (tmax), area under the plasma concentration-
time curve extrapolated to infinity (auc∞), terminal half-life, and bioavailability 
(%F). These pharmacokinetic parameters and the urinary excretion values 
were summarized using descriptive statistics. Dose normalized auc and Cmax 
values (normalized to the 200 mg dose) were compared using anova (analysis 
of variance) to test dose-linearity of exposure.
The analysis on the pharmacodynamic effects of isis 325568 was performed 
on subjects that received all doses and completed the pre- and post-treatment 
glucagon challenge. The analysis concerned the hepatic glucose production, 
the systemic glucose disposal, the glucose auc obtained during the challenges 
and the difference in fasting glucagon and glp-1 concentrations during the 
treatment. Hepatic glucose production was calculated using the Steele equa-
tions for non-steady state conditions as adapted for the use of stable isotopes 
using a pool fraction of 65% [18]. The data was first checked for normality with 
a Shapiro-Wilk test. Two analyses were performed. The first analysis consisted 
of a comparison within each dosing group (week 1 versus week 7) with an 
anova. Results are reported with the estimated differences along with the cor-
responding 95% confidence interval and p values. 
The second analysis consisted of the comparison of active treatment 
vs. placebo. This was analyzed with a mixed model analysis of variance with 
treatment, week and time as fixed factors and all the interactions, and sub-
ject, subject by week and subject by time as random factors. Results are 
given as the least squares mean estimates, the estimated difference with the 
corresponding 95% confidence interval, and the p-value. The data of the 12 
placebo-treated subjects were pooled. 
The analysis for the change from baseline for glucagon was analyzed with 
an ancova with treatment and time as fixed factor, subject, subject by time 
and subject by treatment as random factors and pre-dose value as covariate. 
Results are given as the least squares mean estimates, the estimated differ-
ence with the corresponding 95% confidence interval, and the p-value. While 
it is difficult to draw firm conclusions on the pk-pd relationship from this study, 
a correlation of plasma trough concentration (Cmin) and the pd end-points was 
attempted. Steady-state levels of isis 325568 were achieved by approximately 
4-weeks in this study, with no significant difference between the 4 and 6 week 
Cmin levels. Therefore, the average plasma Cmin values for weeks 4-6 were 
averaged and their relationship with the plasma glucagon levels and the reduc-
tion in glucose auc during the glucagon challenge was explored. All statistical 
analyses were done using sas software (version 9.1.3; Cary, nc). 
results
baseline characteristics
Sixteen male subjects were dosed in the single dose part of the study and had 
an age range of 18 to 63 years and a body mass index (bmi) between 19 and 30 
kg/m², and all subjects completed the study. In the multiple dose part of the 
study a total of 43 male subjects were dosed, ranging in age from 18 to 64 years 
(mean 39 yrs). The bmi ranged from 18.6 to 29.7 kg/m² (mean 23 kg/m²) and the 
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baseline glycated hemoglobin levels ranged from 27 to 42 mmol/mol (mean 33 
mmol/mol). During the entire study four subjects were withdrawn; two sub-
jects for non-treatment related intercurrent diseases (anemia, epididymitis), 
one subject for personal reasons and one subject because of an unsuccessful 
pre-dose glucagon challenge. The subjects were replaced and the replace-
ments received the same treatment, except for the subject participating in the 
50 mg dose group of the multiple dose part of the study who developed anemia. 
safety
There were no clinically significant changes in vital signs, ecg recordings and 
routine laboratory parameters in the single and multiple dose part of the study. 
In addition, there were no dose-dependent trends or differences in these 
parameters between placebo-treated and isis 325568-treated volunteers. 
Specifically, renal function parameters such as serum creatinine and urinary 
excretion of ß2-microglobulin (data not shown) were not different between 
the treatment groups. There was a dose-dependent and transient prolonga-
tion of aptt at 1 hr post iv infusion (maximum average increase of 27 sec in 
the 400 mg dose group) which had returned to baseline at 3 hrs post infusion. 
Complement (C5a and Bb), and serum cytokines (ifn-α, il-6, mip-1α, mcp-1) 
showed that there was no indication for meaningful changes at any dose (data 
not shown). 
The most commonly observed treatment-related ae were predominantly 
mild injection site reactions (isrs) that were observed in the multiple dose 
cohorts, particularly at doses exceeding 100 mg. Injection site reactions 
occurred as erythema at the sc injection site with or without itch and/or mini-
mal swelling and resolved spontaneously, although in 6 subjects injection site 
reactions persisted as a small hyperpigmented area. Local lymphadenopathy 
or other signs of symptoms were not observed. 
After iv dosing with 400 mg isis 325568, transient feelings of malaise and 
tiredness, nausea, and headache were observed in 7 of the 8 subjects and was 
accompanied by fever (max temperature 39.3°C) in 4 subjects. These symp-
toms were not observed upon any of the sc administrations.
pharmacokinetics
The drug plasma concentration-time curves followed a poly-exponential pat-
tern (Table 1). Distribution half-life was 1-2 hrs following termination of the 
iv infusion. This rapid distribution phase was followed by at least one much 
slower elimination phase. Apparent terminal elimination half-lives following 
the final sc dose administered in the multiple dose cohorts ranged from 14 to 
21 days, consistent with slow drug elimination from tissue. Plasma trough lev-
els were stable after the third sc dose suggesting that steady-state levels were 
reached. Cmax and auc increased in a dose-dependent and linear fashion over 
the dose range studied (50 mg to 400 mg), both after the iv and sc single dose 
administration. Upon repeated dosing, Cmax or auc did not increase compared 
to first dose which is consistent with the rapid uptake of the aso into tissues of 
distribution and confirms a lack of accumulation in plasma. isis 325568 was 
well absorbed after sc administration with absolute bioavailability ranging 
between 72-101%. While aucs were similar following sc injection and iv admin-
istration, Cmax following sc administration was approximately 4-fold lower and 
reached later. Urinary excretion was low, with less than 5% of the administered 
dose excreted over 24 hr following sc injection. After iv administration of 400 
mg approximately 10% of the dose was excreted in urine over 24 hr. 
pharmacodynamic evaluation
Fasting plasma glucagon levels increased dose-dependently after multiple 
doses of isis 325568 (Figure 1). The increase in glucagon levels for the inte-
grated response (entire time profile over treatment period) between placebo 
(60.2 ng/mL) and active treatment was significant for the 400mg dose (73.9 
ng/mL) and amounted to 23% (p=0.017). The baseline corrected average 
change in fasting plasma glucagon compared to placebo increased for the 400 
mg dose only. The change in glucagon concentrations at this dose was 25 ng/
ml (p=0.007), while the glucose levels for both treatments were similar (pla-
cebo vs. 400 mg treatment: 5.1 vs.5.2 mmol/L before dosing and 5.1 and 4.9 
mmol/L after dosing (ns), respectively).
Treatment with gcgr antisense also affected hgp under conditions of selec-
tive hyperglucagonemia and basal insulin concentrations. Here it was shown 
that after initiation of the glucagon infusion, plasma glucagon levels rapidly 
increased and reached a steady-state concentration that was about 2-fold 
higher than the pre-infusion concentration in all cohorts. During the pre-treat-
ment glucagon challenges, hepatic glucose production (hgp) increased rapidly 
upon initiation of the glucagon infusion from 1.0 to 2.5 mmol/min (Figure 2). 
hgp remained 2-fold higher than basal levels for the first 90 minutes of the glu-
cagon infusion and subsequently showed a gradual decline by the end of the 
glucagon infusion period. The rate of glucose disposal was more or less con-
stant during the glucagon infusion. The glucagon infusion resulted in a rapid 
elevation of plasma glucose levels from a basal level of 5.5 mmol/L to a steady-
state level of 12 mmol/L (Figure 3). This effect was consistent between all the 
treatment groups. After treatment with isis 325568, the glucagon profile was 
highly similar, but the increase in hgp was blunted, while the rate of disappear-
ance was unaffected (Figure 2 and Table 2). As a consequence, the increase in 
plasma glucose levels during the hyperglucagonemic period were blunted after 
the 200 and 400 mg dosing regimen (Figure 3). The effect assessed by the glu-
cose auc values during the 3-hour challenge was 6% (ns) in the 200 mg group 
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and 24% (p<0.0001) in the 400 mg group. Variability and lack of consistency in 
the glp-1 assay did not allow interpretation of this parameter. 
drug concentration and pd response relationship
The relationship between changes in plasma glucagon levels and the reduction 
in glucose auc during the glucagon challenge, by dose group, plotted against 
the average trough concentrations of isis 325568 obtained over 6 weeks of 
treatment is shown in Figure 4. The Cmin values correlated with the change 
in both pharmacodynamic end-points. The changes in plasma glucose and 
glucagon levels in the 400 mg group occurred at average pk trough concentra-
tions of approximately 13 ng/mL and higher. Pre- and post-treatment changes 
in plasma glucose and glucagon levels were minimal and not statistically 
significant at the lower doses (100 and 200 mg), which correlated with lower 
average pk trough concentrations. 
discussion
This study investigated the effects and pharmacokinetics of isis 325568, a sec-
ond-generation antisense phosphorothioate oligonucleotide. As there was no 
clinical experience with isis 325568, the dose range chosen for this study which 
was approximately 0.6 to 6 mg/kg body weight was based on the pre-clinical 
data of isis 325568, and clinical experience with other 2´-moe-modified asos 
that were demonstrated to be well-tolerated in healthy volunteers at doses up 
to 600 mg and treatment durations of 12 weeks [13]. Six weeks of treatment 
with isis 325568 caused a significant inhibition of the glucagon-mediated 
increase in hepatic glucose production.
This study extends the safety findings of 2´-moe-modified asos as no 
clinically relevant changes in vital signs, ecg, clinical chemistry or urinalysis 
occurred after weekly doses up to 400mg. Particularly, fasting hypoglycemia 
was not observed and isis 325568 was not associated with untoward renal 
effects. The latter finding is important as one of the metabolic routes of asos 
is uptake by proximal tubular cells, followed by sequestration and break-down 
in lysozomes. Apparently, accumulation of isis 325568 in the proximal tubules 
in humans does not affect renal function, which is consistent with the find-
ings in animals. The flu-like symptoms, which possibly reflect a mild systemic 
inflammatory reaction, were observed at the 400 mg iv dose only and not after 
sc administration of the same dose. These findings are consistent with previ-
ous observations with this class of asos [13;19]. Local injection site reactions 
occurred frequently at weekly doses ≥ 100 mg with an incidence of ~60%. The 
incidence of injection site reactions appears to be lower with the more recent 
antisense compounds (data on file isis Pharmaceuticals Inc., usa). 
The pharmacokinetics of isis 325568 showed an almost complete bioavailabil-
ity after sc dosing with terminal elimination half-lives in order of 14-21 days, 
consistent with slow drug elimination from tissue. Cmax and auc increased in 
a dose-dependent and linear fashion over the dose range studied (50 mg to 
400 mg), both after the iv and sc single dose administration. However, consis-
tent with the rapid uptake of the aso into tissues, Cmax or auc did not increase 
upon repeated dosing. Urinary excretion over 24 hr amounted to only 5% of 
the administered dose, with a trend for higher excretion (10%) after iv admin-
istration of the 400 mg dose. The latter observation suggests a higher unbound 
fraction in plasma available for filtration. 
This study showed that 6 weeks of treatment with isis 325568 translated 
into a significant inhibition of the glucagon-mediated increase in hepatic 
glucose production. This effect was observed in the 400 mg dose cohort and 
amounted to approximately 15-20 % inhibition in hgp. As in non-human pri-
mates ~60% knock-down is associated with a 30% reduction in hgp, it seems 
that the level of knock-down in humans after treatment with the 400 mg dos-
age regimen was in the same order of magnitude. Proof of pharmacology in 
humans was further demonstrated by the gradual increase in fasting glucagon 
levels, a validated biomarker for this target based on preclinical studies. The 
increase was 23% (ns) in the 200 mg dose group and 41% (p=0.007) for the 
400 mg treatment. The most likely explanation of the elevated basal glucagon 
levels is a feedback of the pancreas as a response to diminished hepatic gcgr 
receptor availability. However, it can also be a direct effect as pre-clinical stud-
ies with gcgr asos showed activation of pancreatic alpha cells (evidenced by 
increased plasma concentrations of active glp-1). As a result of the increase 
in active glp-1 induced by gcgr aso, islet insulin content is increased, insulin 
secretion is preserved and glucose tolerance is improved [12]. Importantly, it is 
unlikely that hypoglycemia resulted in elevated glucagon levels as none of the 
volunteers had low glucose levels throughout the entire observation period. 
Although it is recognized that it is difficult to draw firm conclusions on the 
pk-pd relationship from this study, it appeared that average trough plasma 
concentration of isis 325568 correlated with the change in both the pharma-
codynamic end-points (plasma glucagon levels as well as reduction in glucose 
auc during the glucagon challenge). Importantly, plasma trough concentration 
are reflective of tissue drug concentration and we found that the changes in 
plasma glucose and glucagon changes in the 400 mg group occurred at aver-
age pk trough concentrations of approximately 13 ng/mL and higher. These 
levels are predictive of liver drug concentrations of 80-100 µg/g liver tissue, 
which have been shown to produce pharmacology in preclinical models. 
In conclusion, 6 weeks treatment with gcgr aso in healthy volunteers resulted 
in the first demonstration of pharmacology in humans. These results support 
further evaluation of aso-based therapies against the glucagon receptor in 
patients with type 2 diabetes mellitus. 
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table 1 Mean ± standard deviation of pharmacokinetic parameters for 
isis 325568 after the initial 1-hour intravenous infusion (a) and final sc 
administration (b) in the multiple dose part of the study.








Cmax (µg/mL) 8.2 ± 0.6 14±1.6 30 ± 7.0 54 ± 18
auc 0-inf (µg*hr/mL) 16 ± 2.0 33 ± 4.5 66 ±9.3 121 ± 14
CI (L/hr) 3.1 ± 0.4 3.0 ± 0.4 3.1 ±0.4 3.3 ± 0.4
Vss (L) 6.5 ± 0.9 6.7 ± 1.0 7.5 ± 1.0 9.1 ± 1.2
T½_distribution (hr) 2.0 ± 0.04 2.2 ± 0.3 2.5 ±0.3 2.7 ± 0.3









Cmax (µg/mL) 1.9 3.1±0.9 7.0 ± 1.6 9.2 ± 2.2
Tmax (hr) 4.0 3.4 ± 2.0 2.6 ± 1.0 2.4 ± 0.6
auc 0-24h (µg*hr/mL) 15 23 ± 3.9 51 ± 6.6 77 ± 15
auc 0-168h (µg*hr/mL) 16 25 ± 4.3 56 ± 6.5 88 ± 19
% F 101 76 ± 11 86 ± 13 72 ± 13
T½_distribution (hr) 2.3 3.3 ± 1.1 3.4 ± 1.1 4.4 ± 0.9
T½_final (days) 14 21 ± 8.9 19 ± 3.4 18 ± 11
Cmax: maximal concentration; auc0-inf/0-24h/0-168h : Area Under the Curve for t= 0 min to infinity, 24 hrs, 168 
hrs; Cl: Clearance; Vss: volume of distribution; T ½_distribution/_ final: half-life associated with distribution/
final phase; % F: percentage bioavailability.
























































































































































































































































































































































































































































































































































































































































table 2 Mean (sd) values in hepatic glucose production (hgp), glucose rate 
of disappearance (rd), and time-corrected area under the curve for glucose 
(auc/t) during the hyperglucagonemic challenge before (pre) and after (post) 
treatment for 8 weeks with different dose of isis 325568 or placebo. The point 
estimate of the difference (along with the corresponding 95% confidence 
interval (95% ci) and p-value are reported.
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figure 3 Mean glucose values during glucagon challenge for the different 
dose groups before (closed circles) and after 8 weeks treatment (open 
squares) with isis 325568.
figure 1 Time course of plasma glucagon levels (mean and sd) during 
multiple dose treatment with isis 325568. Intravenous doses are indicated  
by the dashed arrows and solid arrows indicate the weekly sc doses. For clarity 
the sd bars are given for the placebo and 400 mg dose regimen only.
figure 2 Time course of hepatic glucose production (hgp) and rate  
of glucose disposal (rd) before and after 8 weeks treatment with placebo  
(left panel; n=13) or 400 mg isis 325568 (right panel; n=8).
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figure 4 Plots of steady state trough concentration of isis 325568 after 
6 weeks of treatment versus the change in glucose auc during the glucagon 
challenge (a) and change in glucagon (b).
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Modeling glucose metabolism is challenging because of the complex inter- 
actions between the hormones involved and the simultaneous effect on 
glucose in the system. This is particularly true for models incorporating the 
contribution of glucagon to glucose homeostasis; in fact models incorporating 
modulation the glucagon receptor have not been described yet. Therefore we 
have developed a semi-mechanistic model to describe the glucagon-insulin-
glucose homeostasis in 36 healthy subjects during a glucagon challenge. 
Briefly, this challenge consisted of a 3 hrs infusion of somatostatin to block 
endogenous release of insulin and glucagon with simultaneous infusion 
of high dose glucagon and physiological dose insulin. The model captured 
glucagon and glucose dynamics, including the amplifying effects of glucagon 
on hepatic glucose production with the magnitude of the effect being 
dependent on the prevailing insulin concentration. Glucagon production was 
inhibited by elevated glucose concentrations. We observed a rapid increase of 
the glucose concentration in response to glucagon followed by a slow decrease 
in the hgp, which is consistent with the internalization of glucagon receptors 
(gcgr) upon stimulation by glucagon, which was captured by incorporating 
an effect compartment. The model also captured the effects of glucose on 
insulin production and the insulin-independent and insulin-dependent effect 
on glucose elimination. 
This model, based on glucagon challenge data, could contribute to a better 
understanding of pathophysiology of diabetes mellitus. It describes the general 
trend and can therefore serve as a basis for drug development. Furthermore, an 
extension of this model could probably be incorporated in the recently devel-
oped automated, bihormonal, bionic pancreas for type 1 diabetes mellitus 
patients.
introduction
In recent years, an increased interest has re-emerged in the role of the glu-
cagon receptor (gcgr) in diabetes and its utility as a therapeutic target [1;2]. 
In healthy subjects the endocrine pancreas regulates glucose production and 
metabolism by a synchronized reciprocal release of insulin and glucagon in 
response to changes in blood glucose levels, free fatty acids (ffa), amino acids, 
incretin hormones (such as glp-1 and gip), among many other signals. In type 
2 diabetes mellitus (t2dm), there is evidence for a dysregulation of glucose-
insulin-glucagon interaction [3-5]. Elevated fasting and postprandial glucagon 
concentrations in t2dm patients could suggest a combination of dysregulated 
glucagon secretion and insulin resistance. The most important consequence 
of chronic hyperglucagonemia seems to be related to increased glucose 
production (gluconeogenesis but not glucogenolysis) aggravating hyperglyce-
mia in diabetic patients [6]. Understanding the contribution of glucagon on the 
glucose metabolism is important for (patho)physiological insight and may also 
be important in guiding drug development for compounds targeting glucagon.
Glucose metabolism is challenging because of the complex interactions 
between the hormones involved and the simultaneous effect on glucose in the 
system. More than 3 decades ago Bergman et al. [7] developed the first model 
for glucose regulation. With help of this model the estimation of glucose tis-
sue uptake sensitivity to insulin levels hypothesis was corroborated in clinical 
experiments, the biphasic insulin secretion profile was defined and the rela-
tionship between insulin and glucose concentrations as a possible mechanism 
of the disease was suggested.
Basic models in animals and in vitro have helped to understand underly-
ing mechanisms and to explore new possible therapeutic targets for diabetes 
[8-10]. Farhy et al. [9] integrated glucagon into the physiological model, creat-
ing an explanation of the system from an intercellular level, suggesting high 
glucagon concentrations as lack of inhibition by glucagon counter regulation 
in ß-cell deficiency.
Several models based on clinical endpoints in healthy subjects and/or 
t2dm patients have been developed to describe and better understand the 
relationship between glucose and insulin [11-17]. pk/pd models have quickly 
evolved from minimalistic models describing glucose plasma concentrations 
to complex system pharmacology models that take multiple interactions into 
account [13;16-19]. Based on earlier models we can describe the general trends 
between insulin and glucose very well, and find that additional regulators in 
glucose homeostasis are required to improve our understanding of drug action 
in healthy volunteers, but more important in diabetes patients. For instance, 
since 2008 mathematical models of glucagon secretion and glucagon counter 
regulation based on in vitro studies were published [9]. Recently, a semi-mech-
anistic, integrated glucose-insulin-glucagon model was developed to assess 
the effects of individualized glucokinase activator on glycemic response 
[20-22].
However, models incorporating contribution of glucagon to glucose homeo-
stasis while modulating the glucagon receptor, have not been described yet. 
Therefore we developed a semi-mechanistic model to describe the glucagon-
insulin-glucose homeostasis in healthy subjects during a glucagon challenge. 
Briefly, this challenge consisted of a 3 hrs simultaneous infusion of high glu-
cagon concentrations (supra-physiological) and insulin, while somatostatin 
was given to block endogenous release of these hormones. The model was 
subsequently used to predict the influence of the amount of hepatic glucagon 
receptors in the glucose plasma availability and to perform simulations with 
hypothetical scenarios for altered glucagon conditions, such as a glucagon 
challenge. 
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Thirty-six healthy male volunteers participated in the clinical study, which was 
conducted at a single center (chdr). Their mean (±sd) age was 40.5 ±18.3 years, 
weight 78.9 ±10.3 kg, body surface area 1.98 ± 0.156 m² and body mass index 
(bmi) 24.0 ±3.1 kg/m². Mean fasting glucose and glycosylated hemoglobin A1c 
baseline values were 5.1 ±0.4 mmol/L and 5.2 ±0.3%, respectively. The pro-
tocol was approved by the Central Committee on Research involving Human 
Subjects of the Netherlands (ccmo). Written consent was obtained from all 
participants included in the study. The study has already been published [23].
study design
Subjects were required to continue their normal diet and activities. After an 
overnight fast, the hyperglucagonemic clamp test was performed, consist-
ing of two phases: a run-in period of 3 hrs to achieve stable glucose isotope 
enrichment and a 3 hr pancreatic clamp study (Figure 1). After a priming dose of 
5 mg.kg¯¹, [6,6-²H²] glucose was infused continuously throughout the study at 
a rate of 0.05 mg.kg¯¹.min¯¹ (Cambridge Isotope Laboratories, ma, usa). The 
pancreatic clamp study consisted of a simultaneous 3 hrs infusion of soma-
tostatin (0.1 µg.kg¯¹.min¯¹; ucb, The Netherlands), glucagon (3 ng.kg¯¹.min¯¹; 
Novo Nordisk, The Netherlands) and insulin (4 mU.m¯².min¯¹; Novo Nordisk, 
The Netherlands). A second catheter was inserted into a contra-lateral dorsal 
hand vein for blood sampling. The hand was placed in a heated-box (50°C) to 
arterialize venous blood for labeled glucose sampling. Venous blood samples 
were drawn to determine (non-) labeled glucose, glucagon, and insulin con-
centrations. Samples for isotope analyses, glucose, glucagon and insulin were 
collected every 15 minutes from 30 minutes before the start of the challenge 
until the end of the glucagon challenge (t=360 min). After the challenge capil-
lary bedside (finger prick) glucose was measured for informative purposes in 16 
subjects at 420, 450 and 480 min. 
laboratory analysis
Blood samples for insulin were collected in plain tubes and analyzed using 
standard validated immune-radio-metric assays (Biosource Europe s.a., 
Belgium; assay cv 5.9-7.9% for insulin). Glucagon samples were collected in 
plain tubes with aprotinin (Trasylol™ (500 kie/50 µl) Bayer, The Netherlands) 
and analyzed using a radioimmunoassay (Linco research, Missouri, usa; assay 
cv 4.3%). Blood samples for glucose and [6,6-²H²] glucose were analyzed 
using a validated gas chromatography with mass spectrometry as detection 
method as described previously [24]. All samples were analyzed in batches to 
reduce assay variability.
modeling glucagon challenge 
inhibition
Somatostatin infusion during the glucagon challenge, which inhibits the 
endogenous glucagon and insulin secretion, was modeled by an inhibitory 
function Ii (t) equal to 1, except during the inhibition, when they take on a lower 
– but still non-negative – value. 
The inhibitory functions I1(t) and I3(t) in, respectively, equations {4} and {6}, 
are given by: 
{1}
Where Imax denotes the maximal inhibition (i.e., 0 < Imax ≤ 1). The function H
(t; tstart, tend,α i) denotes a smooth step function defined by:                    {2}
Here α i > 0 is the rate at which the inhibition reaches its maximum value ≈ 
Imax. The times tbegin and tend denote when the inhibitions begin and end.
infusions
The functions Q1(t), Q2(t) and Q3(t) which model the infusions in, respectively, 
equations {4}, {5}, and {6}, are given by:
{3}
Where Step (t; Tbegin, Tend ), is a simple step-function, which is equal to 1 for 
Tbegin < t < Tend  and 0 elsewhere. 
structural model development
Using population approach nonlinear mixed effects modeling, glucose-, insu-
lin- and glucagon data from a glucagon challenge in healthy volunteers were 
simultaneously analyzed. First, the somatostatin effect was modeled as an on-


















− k − k · A + Q
dt
= k · I − k A
l  (t) = 1 − × H (t; t ,t , α  ), (i = 1,3)
F (x)   =                 −        −    R  ·       = 0 
0                                                      for 0 ≤ t ≤ t 
1 − e                                                for t        < t < t     





















H (t; t , t ,α  ) = begin end i
Q (t) = Q         × Step (i,maxi     t, T ,T     ), (i = 1, 2, 3)begin end
R  =            , 
k in1
kout1
1 R  =            , 
k in2
kout2
2 R  =            , 
k in3
kout3






     =            ,  A       = R  A       ,  A       = R  A       
R1
A2,ss
A  1,ss 3,ss 2,ss3 2,ss44,ss





(t–t         )– α   i begin






















− k − k · A + Q
dt
= k · I − k A
l  (t) = 1 − × H (t; t ,t , α  ), (i = 1,3)
F (x)   =                 −        −    R  ·       = 0 
0                                                      for 0 ≤ t ≤ t 
1 − e                                                for t        < t < t     





















H (t; t , t ,α  ) = begin end i
Q (t) = Q         × Step (i,maxi     t, T ,T     ), (i = 1, 2, 3)begin end
R  =            , 
k in1
kout1
1 R  =            , 
k in2
kout2
2 R  =            , 
k in3
kout3






     =            ,  A       = R  A       ,  A       = R  A       
R1
A2,ss
A  1,ss 3,ss 2,ss3 2,ss44,ss





(t–t         )– α   i begin






















− k − k · A + Q
dt
= k · I − k A
l  (t) = 1 − × H (t; t ,t , α  ), (i = 1,3)
F (x)   =                 −        −    R  ·       = 0 
0                                                      for 0 ≤ t ≤ t 
1 − e                                                for t        < t < t     





















H (t; t , t ,α  ) = begin end i
Q (t) = Q         × Step (i,maxi     t, T ,T     ), (i = 1, 2, 3)begin end
R  =            , 
k in1
kout1
1 R  =            , 
k in2
kout2
2 R  =            , 
k in3
kout3






     =            ,  A       = R  A       ,  A       = R  A       
R1
A2,ss
A  1,ss 3,ss 2,ss3 2,ss44,ss





(t–t         )– α   i begin





exploring the role of glucagon in glucose homeostasis
84
modeling glucagon’s influence on glucose homeostasis
85
66
was expanded to an inhibitory function (Equation 1). The first-order conditional 
estimation method with interaction (foce i) was used. The log-likelihood 
ratio test was used to discriminate between hierarchical models, based on the 
objective function value (ofv), where p<0.05 [decrease ofv of at least 3.84 
points for one degree of freedom, Chi-square (χ²) distribution] was considered 
to be statistically significant. Various goodness-of-fit plots such as: obser-
vations vs. population predictions, observations vs. individual predictions, 
weighted residuals vs. time, (conditional)weighted residuals vs. observed con-
centrations, histogram and/or qq plots of the post hoc individual estimates of 
etas (when etas were available), population and/or individual predictions vs. 
observed individual or population concentrations; were considered for diag-
nostic purposes. Covariate screening was performed by graphical analysis and 
analysis of the correlation of the post hoc individual estimates of eta for each 
parameter versus the covariate values. Three different error types were tested 
(additional, proportional and both). A model was considered acceptable if the 
conditional weighted residuals with η–ε interaction (cwresi) was between -2 
and 2. Whenever a new parameter was introduced or the robustness of the 
model was to be evaluated, the mean population predictions plotted against 
the observations was performed. The compartmental semi-mechanistic final 
model structure that best described the observations, including the feedback 
mechanisms, is illustrated in Figure 2.
glucagon (a1 in nanogram)
Glucagon dynamics was described by a turnover equation (Equation 4). The 
production term (kin1) is taken inversely proportional to the amount of glucose 
(A²), as glucagon secretion by α-cells in the pancreas is inhibited by plasma 
glucose [25;26]. 
{4}
Glucagon elimination was modeled by a first order reaction term with a rate 
constant kout1, and glucagon infusion was modeled by a function Q1(t).
plasma glucose (a2 in grams)
Glucose dynamics was described by a turnover equation with hepatic glucose 
production (hgp) and insulin-dependent elimination: 
{5}
Glucagon is a potent stimulus of hepatic glucose production, with the mag-
nitude of the effect being dependent on the prevailing insulin concentration; 
increasing insulin levels dampen the glucose production [27]. It is known that 
continuous glucagon infusion results in glucagon receptor internalization (A4). 
Intestinal incretin hormones glp-1 and glucose-dependent insulinotropic 
polypeptide (gip) were not included in our model, because all subjects were 
in a fasting state. Incretin hormones are only released during absorption of 
orally taken meals and then stimulate pancreatic ß-cells to secrete insulin [28]. 
Furthermore, the stimulatory effect of autonomic nervous system on hepatic 
glucose production has not been incorporated in our model, because our pre-
vious study showed that changes in the autonomic nervous system tone do 
not contribute significantly to the effects of the glucagon challenge [23]. 
Elimination of plasma glucose, which consists of glucose uptake by the liver 
and muscles is modeled by an insulin independent term (kout2A2) representing 
e.g. brain glucose consumption and an insulin dependent term (kout2dA2·A³) 
The direct inhibition (negative feedback) of plasma glucose level (A²) on the liver 
(hgp) via glut-1 transporter is incorporated in the equation as well. Labeled 
glucose infusion was modeled by a function Q2(t). Labeled glucose infusion 
was assumed to have the same disposition properties as total plasma glucose 
[23;24], therefore no difference in glucose has been made. Labeled glucose and 
enrichment measurements were not considered in the model. 
insulin (a3 in milliunits)
Insulin dynamics was described by a turnover equation. Since insulin secre-
tion by ß-cells in the pancreas is stimulated by plasma glucose, the production 
term is taken proportional to the amount of glucose A². 
This results in the equation: 
{6}
Insulin elimination was modeled by a first order elimination process with rate 
constant kout3, and insulin infusion was modeled by a function Q3(t), according 
to equation 3.
internalization of glucagon receptors-effect 
compartment (a4-dimensionless)
We observed a rapid increase of the glucose concentration in response to glu-
cagon followed by a slow decrease in the hgp, which is consistent with the 
internalization of glucagon receptors (gcgr) upon stimulation by glucagon 
[23;29;30]. Krilov et al. [29] have previously shown that, upon 30 minutes of 
glucagon stimulation, gcgr are internalized in vivo. This internalization of the 
gcgr was captured by incorporating an effect compartment (A4). With this we 
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the model (Equation 5). The rate constant of removal from the effect compart-
ment characterized the effect delay.
{7}
In the equations 4-7 constitute a coupled system of feedback models: the Glu-
cagon-Glucose system interacting with the Glucose-Insulin system through 
the effect of hepatic glucose production.
data analysis and model evaluation
The software used for the analysis included: promasys v7.1 (promasys bv, 
Leiden, The Netherlands) for the database storing and exporting, nonmem 
v7.2.0 (Icon Development Solutions, Ellicott City, md, usa) for the numerical 
estimations for the established equations [advan 13; tolerance 8], gnu Fortran 
(gcc) 4.6.0 as compiler and R v2.13.1 (R Foundation for Statistical Computing, 
Vienna, Austria) for the predictions (simulations), database editing, system 
solution and graphics elaboration, and matlab R2013a (MathWorks, Natick, 
ma, usa) for simulations.
results
A semi-mechanistic model simultaneously describing glucagon, plasma 
glucose, insulin and glucagon receptor internalization, during a hyperglu-
cagonemic challenge was developed. The study cohort investigated in this 
study covers a broad range of individual data for the model. For each of the 36 
subjects, in total 16x glucagon-, 16x glucose- and 16x insulin concentrations 
before and during the glucagon challenge were measured, and were used for 
the model. The initial values at steady state for the three compartments were 
obtained from the first observations (before the challenge was started), the 
volumes of distribution were obtained from the literature and used as initial 
estimates [13] and limits were given to values that would be physiological. 
Also, inter- and intra-individual variability (iiv) was considered but could not be 
identified given the data.
model evaluation / simulations
Fitting the model to the data resulted in the following baseline values for glu-
cagon, glucose, insulin and effect compartment: 
BL1 = 1170 ng, BL2 = 4.20 g, BL3 = 17.7 mU, BL4 = 4.63 x 106 {8}
 and volumes of distribution of the Glucagon-compartment, the Glucose com-
partment and the Insulin compartment: 
V¹ = 21.1 L, V² = 4.44 L, V³ = 1.53 L respectively. {9}
This results in the following baseline concentrations for the glucagon, plasma 
glucose and insulin:
C¹ = 55.45 ng/L, C² = 0.946 g/L, C³ = 11.6 mU/L respectively. {10}
The baseline values were used as initial values: Ai(0) = BLi.
Fitting the model to the data yields parameter estimates listed in Table 1, 
where the values for kin1, kin2, kin3 and kin4 are computed from the estimated 
values for kout1, kout2, kout2d, kout3 and kout4, and the estimates of the baseline 
amounts BLi (i = 1, …,3) obtained from (Equation 8).
Parameters involved in the glucagon challenge and the infusions are listed 
in Table 2.
In computing the infusion rates Q¹ and Q³ in Table 2, we have assumed that 
the average weight is 80 kg and the average body surface area 1.984 m². 
Four representative individuals were selected from the whole dataset and 
are presented in Figure 4. The medians of the simulated individual concentra-
tion-time profiles are plotted over the observed profiles of glucose, glucagon 
and insulin during baseline and during challenge. Individual diagnostic plots 
for the evaluation of the quality of the model fit, illustrate that the model 
described the data. During challenge, glucagon data show a decreasing trend, 
which is captured by the model. As inter- and intra-individual variability could 
not be identified, the height of the glucagon concentrations could not be 
captured on an individual level. For plasma glucose concentration during chal-
lenge, the increase in glucose levels over time is well captured by the model. 
There seems to be a slight decreasing trend in glucose concentrations at the 
end of the challenge, which is better fitted by including the effect compart-
ment (A4). Even though the fitting is not completely optimal towards the end of 
the challenge, because it does not describe in some individuals the diminished 
response to glucagon (glucagon desensitization), inter-individual variability 
could better explain this phenomenon.
Regarding the recovery phase of plasma glucose levels after challenge, only 
assumptions were made based on the minor finger prick glucose data points. 
No laboratory data were collected in the recovery phase.
During challenge a standard insulin dose was infused, and endogenous 
insulin production was inhibited by somatostatin, therefore insulin concentra-
tions are almost stable during challenge.
However, the predicted insulin concentrations exhibit a peak at the start 
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artifacts caused by the step function, involving instantaneous onset and ter-
mination, while the inhibition of insulin release by somatostatin takes time 
as does the release of endogenous insulin upon cessation of somatostatin. 
We decided to not further model this artifact. Firstly, the exact nature of the 
simultaneously occurring increase in insulin (by the infusion) and the decline 
in endogenous insulin (by somatostatin) is not very well known. Secondly, the 
additional parameters required to describe a gradual increase would cause 
over-parameterization of the model. 
In addition to the four representative individuals, Figure 5 shows the diag-
nostic plots of the entire dataset. It clearly shows that the general trend of all 
glucagon and glucose data is well captured by the model. The insulin data is 
also well captured with exception for the peaks at the start and end of the chal-
lenge, for reasons mentioned before.
Concentration population predictions vs. conditional weighted residuals 
graphs for glucagon, glucose and insulin are shown in Figure 6. The glucagon 
and glucose observations are randomly spread around the identity line and 
most observations lie within the acceptance criterion. The insulin conditional 
weighted residuals over time plots show a clear structural bias; the high pre-
dicted concentration range is overpredicted (peaks at the start and end of 
challenge), which is corrected for towards the lower predicted concentration 
range that, as a result, ends in underpredicted values. The steady state condi-
tions and calculations are supplied in Appendix A. 
discussion 
This glucagon receptor (gcgr) modeling approach was a practical tool to 
describe the glucagon-insulin-glucose homeostasis in healthy subjects dur-
ing a glucagon challenge [23]. Although this model represents a simplification 
of complex physiology, the main counter-regulatory elements in the glucose 
regulation system (glucagon and insulin) were used to describe glucose’s pro-
file in a semi-mechanistic way. Application to clinical data showed that the 
model is able to describe the levels of insulin, glucagon and glucose before and 
during the glucagon challenge. 
Somatostatin was infused during the glucagon challenge to suppress the 
endogenous hormone production. The model assumed a maximal inhibi-
tion (Imax) of 1, representing 100% inhibition. Although there is consensus in 
the literature on the inhibiting effect of somatostatin on endogenous hor-
mone production, the extent of maximal inhibition has not been irrefutably 
demonstrated. The measured individual glucagon profiles (Figure 4) show a 
decreasing trend in the glucagon concentrations during the constant glucagon 
infusion period. The glucagon pattern could be explained by a small reduction 
of endogenous production on top of the glucagon infusion or the increasing 
plasma glucose concentration that have an inhibiting effect on the remaining 
endogenous glucagon excretion. 
For the subjects in this study, glucagon levels at baseline were higher when 
plasma glucose levels were lower. This could be explained by the glucose-
dependent regulation of glucagon secretion in the α-cell, as reported in animal 
studies [26;31]. At low glucose concentrations, the moderate activity of Katp 
channels situates the α–cell membrane potential in a range that allows the 
opening of Na+ and Ca²+-channels triggering the exocytosis of glucagon gran-
ules and vice versa. 
The amount of plasma glucose concentrations in this model (Equation 5) is 
highly dependent on glucagon (A¹) because during the glucagon challenge a 
supraphysiologic concentration of glucagon was reached. The effect of insulin 
infusion results in glucose uptake by fat and muscles and a reduction of the 
supply of gluconeogenic precursors reaching the liver. The data of the study 
of Sindelar et al. [32] strongly suggest that the liver responds directly, rapidly, 
and sensitively to the plasma insulin levels by a reduction in hgp. The slight 
decreasing trend in glucose concentrations at the end of the challenge has not 
been completely captured by the effect compartment (internalization of glu-
cagon receptors). No data were collected for the recovery phase after stopping 
the glucagon challenge. Therefore, no firm conclusions can be drawn regarding 
the recovery phase, only assumptions based on the minor finger prick glucose 
data points. 
Insulin and glucagon are fundamental components of the regulator mecha-
nisms that control glucose homeostasis. These counter-regulatory hormones 
help to keep the blood glucose level within optimum limits. In this work, the 
insulin, glucagon and glucose interactions following a glucagon challenge have 
been described in a single model. The adequate descriptive performance of this 
model has been confirmed by the diagnostic plots per subject and for the total 
population. 
This model, based on glucagon challenge data, could contribute to a better 
understanding of pathophysiology of diabetes mellitus. It describes the general 
trend and can therefore serve as a basis for drug development. Furthermore, an 
extension of this model could probably be incorporated in the recently devel-
oped automated, bihormonal, bionic pancreas for type 1 diabetes mellitus 
patients [33].
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In the absence of inhibitions and infusions, i.e., when Ii (t) = 0 for i = 1, 3 and 
Qi (t) = 0 for i = 1, 2, 3 we denote the steady state amounts of the four com-
pounds by An,ss (n= 1,…,4). 
We denote the quotients of kin and kout for each of the four equations by:
 {a.1} 
With this notation, A1,ss, A3,ss and A4,ss can readily be expressed in terms of A2,ss: 
 {a.2} 
When we substitute these expressions into the right hand side of Equation 5 
for dA2/dt, we obtain an equation for x = A2,ss alone:
 
 {a.3} 
The function F(x) is seen to have a unique zero: x = A2,ss = 4.20. For the param-
eter values of Table 1, we obtain: 
R1 = 4914, R2 = 2.16 × 105, R3 = 4.21, R4 = 1.1o × 106, γ = 0.650 {a.4} 
Using these values in the expressions of Equation 5, we obtain for the steady 
state amounts
A1,ss = 1170 ng, A2,ss = 4.20 g, A3,ss = 17.7 mU, A4,ss = 4.63 × 106 {a.5} 
In the light of the estimated volumes, given in Equation 9, the corresponding 
steady state concentrations are:
C1,ss = 55.45 ng/L, C2,ss = 0.946 g/L, C3,ss = 11.6 mU/L {a.6} 
table 1 Parameter estimates for glucagon, plasma glucose, insulin, 
glucagon receptor internalization and volume of distribution. Parameters with 
an asterix denote calculated parameters (not directly estimated by nonmem).
Parameter Estimate Unit
k in1 559* ng · g · min¯¹
k out1 0.114 min¯¹
k in2 275* g · (ng · min)¯¹
k out2 0.00127 (mU · min)¯¹
k out2d 8.26 x 10¯4 min¯¹
k in3 2.09* mU · (g · min)¯¹
k out3 0.496 min¯¹
k in4 655* (g · min)¯¹
k out4 5.94 x 10¯4 min¯¹
table 2 Parameter values involved in glucagon challenge and infusions.  
Parameter Estimate Unit
α¹ 7.00 x  10¯
4 min¯¹
α³ 1.18 x 10¯¹ min¯¹
Q¹* 240 ng · min¯¹
Q2(5 min bolus)* 0.001 g · kg¯¹
Q2* 0.00001 g · kg¯¹ · min¯¹
Q3* 7.936 mU · min¯¹
* fixed parameters
figure 1 Glucagon challenge; infusion of somatostatin, glucagon, insulin 
and labeled glucose.
Basal period       Hyperglucagonaemic period
0 min  – – – 5 min 5 min  – – – 180 min 180min – – – 360 min 
[6.6'–2H2] glucose  
bolus 5 mg.kg¯¹
[6.6'–2H2] glucose  continuous 0.05 mg.kg¯¹ .min¯¹  
Somatostatin 0.1 μg.kg¯¹.min¯¹ 
Glucagon 3 ng.kg¯¹.min¯¹ 
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figure 2 Schematic representation of the model. Full arrows indicate flows, 
broken arrows indicate control mechanisms, dotted arrows indicate infusion 
of somatostatin, glucagon, insulin and labeled glucose.
figure 3 The inhibition functions I1(t), with α = 0.0007, and I3(t), with  
α = 0.118, for tbegin = 5 and  tend = 180 min.
figure 4 Representative profiles for glucagon, glucose and insulin of four 
typical healthy subjects. Observations from the original data set are plotted as 
points.  The lines show the average predicted values of the model. The vertical 
dashed lines represent the time of start and stop of the glucagon challenge 
test.  
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figure 6 Glucose, glucagon and insulin conditional weighted residuals 
graphed versus predicted population concentrations. Data points are plotted 
as circles. The horizontal line is the identity line at zero and the dotted line 
represents the acceptance criterion.   
figure 5 Diagnostic plots representing the mean population prediction 
(black) over time for glucagon, plasma glucose and insulin, with the obser-
vations (circles).The vertical dashed lines represent the time of start and 
stop of the glucagon challenge test.  
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In this thesis, a variety of human studies are described that were designed to 
investigate the role of glucagon in glucose homeostasis in healthy volunteers 
and type 2 diabetes (t2dm) patients. 
In non-diabetic subjects glucagon is released into the bloodstream when 
circulating glucose level is low. The main physiological role of glucagon is to 
stimulate hepatic glucose output, thereby leading to increases in glycemia. 
This provides the major counterregulatory mechanism for insulin in maintain-
ing glucose homeostasis in vivo. Compared with healthy subjects, diabetic 
patients have abnormal secretion of not only insulin but also glucagon [1-3]. 
Hyperglucagonemia and altered insulin-to-glucagon ratios play important 
roles in initiating and maintaining pathological hyperglycemic states. These 
observations have initiated a renewed interest in the role of glucagon as modu-
lating glucagon (receptor) action may be a potential target for the therapeutic 
treatment of diabetes. 
Glucagon is one of the therapeutic targets of the currently available incre-
tin-based therapies. A decade ago, before the introduction of incretins, only 
insulin-based therapies were available: biguanides, sulfonylurea and thiazoli-
dinediones. Incretins, glp-1 analogs and ddp-iv inhibitors, stimulate insulin 
release from the pancreatic ß-cells as well as suppress glucagon release from 
the pancreatic α-cells. Drugs that target the glucagon receptor (gcgr) are in 
development, but small molecules were not successful so far due to limited 
drug selectivity, cross-species differences and lack of sustained effects after 
non-competitive blockade. Isis pharmaceuticals Inc. (Carlsbad, usa) devel-
oped a second-generation antisense phosphorothioate oligonucleotide (aso) 
glucagon receptor antagonist (isis 325568). The compound was developed as 
a potential treatment for t2dm patients. Glucagon receptor knock-out mice 
have hyperglucagonemia and α-cell hyperplasia, but their glucose tolerance 
is improved and they develop only a mild fasting hypoglycemia [4]. These 
results are consistent with the pre-clinical experiments with antisense oligo-
nucleotides for the glucagon receptor. Diabetic db/db mice treated with these 
oligonucleotides had lower glucose, triglyceride and free fatty acids blood 
levels, as well as improved glucose tolerance, and they developed hypergluca-
gonemia without apparent effects on α-cell size or number [5]. This approach 
is also accompanied by an increase in glp-1 and insulin levels in Zucker dia-
betic fatty rats and db/db and ob/ob mice [6].
aim of this thesis
This thesis aimed to gain further insight in the role of glucagon and the glu-
cagon receptor antagonist isis 325568 on serum glucose levels in healthy 
volunteers and t2dm patients, in order to explore whether a glucagon receptor 
antagonist may be a useful therapeutic intervention in the treatment of t2dm. 
The specific control of glucagon secretion by pharmacological modulation is 
complex since several components of the α-cell stimulus-secretion coupling 
are also present in ß-cells. Therefore, we also further explored the glucagon 
challenge test, described by Petersen et al.[7], as a tool for investigating the 
effect of a novel gcgr-antagonist.
chapter 1 comprises a general introduction. This chapter starts with a gen-
eral description of glucose homeostasis, pathophysiology of t2dm and current 
treatment options. Pancreatic α-cells and glucagon secretion are fundamental 
components of the regulatory mechanisms that control glucose homeostasis. 
chapter 2 studies the effects of a single protein hydrolysate meal replace-
ment (insuVida™) on postprandial serum glucose, insulin and glucagon levels 
in t2dm patients. We concluded that a single dose of a casein hydrolysate with 
and without the addition of leucine enhanced the carbohydrate-induced insu-
lin response in t2dm patients, resulting in significantly lower plasma glucose 
concentrations compared to placebo and intact casein. However, besides insu-
lin, the secretion of pancreatic glucagon was increased as well during the use 
of all casein-rich meal replacers. This mechanism may have limited the decline 
of plasma glucose concentrations and may be responsible for the absence of 
hypoglycemia. Further research is required to determine the long-term clini-
cal benefit of a low dose of insuVida™, with and without additional leucine. 
This chapter also highlights that investigating only one hormone involved in 
glucose homeostasis (e.g. insulin) as was done in all previous studies with the 
meal replacement product is a too limited approach. Characterization of inter-
ventions that are developed to improve disturbed glucose homeostasis should 
be more comprehensive. 
The aim of the study in chapter 3 was to characterize a glucagon challenge 
test as a tool in diabetes research, by assessing the inter- and intra-individual 
variabilities of the glucagon challenge test and by investigating the activity of 
the autonomic nervous system (ans) during this challenge, as this might have 
an indirect impact on glucose homeostasis. Hepatic glucose production was 
assessed using stable isotope glucose. Furthermore, we determined whether 
human adipose tissue expresses glucagon receptor mrna. The latter may be a 
direct biomarker of pharmacological activity of drugs that affect gcgr action. 
The results of this study in 24 healthy volunteers demonstrated that serum 
glucose concentrations rose rapidly after glucagon infusion, and reached a pla-
teau at 90 min. The time profiles suggested rapid development of tolerance for 
glucagon-induced hyperglycemia. During the glucagon challenge intra- and 
inter individual variabilities for hepatic glucose production, the rate of disap-
pearance of glucose and plasma glucose were approximately 10-15% for all 
variables. Hyperglucagonemia did not affect heart rate variability. In contrast 
to gcgr mrna expression in diabetic mice, we found that the expression level 
of glucagon receptor mrna in human adipose tissue was extremely low, and 
does not qualify as an appropriate biomarker for gcgr knock-down in humans. 
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From this study it was concluded that the standardized 6-hr glucagon chal-
lenge test has a good reproducibility with only limited variability over 6 weeks. 
It is a robust tool to explore in detail the contribution of glucagon in normal and 
altered glucose homeostasis and can also be used to evaluate the effects of 
drugs antagonizing glucagon action in humans without confounding changes 
in ans tone. 
Based on this study the glucagon challenge was expected to be a robust 
tool for glucagon-focused research in diabetes. In chapter 4 the effects of a 
similar glucagon challenge as described in chapter 3 were explored in t2dm 
patients and compared with the glucagon response in healthy volunteers. In 
the patients, the influence of oral antidiabetic drugs on the response to hyper-
glucagonemia was investigated by using a cross-over study design, with and 
without oral antidiabetic drugs. Our results demonstrate that the response to 
a hyperglucagonemic challenge markedly differs between t2dm patients and 
healthy volunteers. Healthy volunteers show a greater increase in hgp upon 
glucagon infusion and also a faster decline in hepatic glucose production than 
t2dm patients. Exogenous insulin suppresses the glucagon-induced hepatic 
glucose production. Furthermore, glucose levels were lower during glucagon 
challenge when t2dm patients stopped their oral medication for two weeks 
and receiving higher insulin doses than patients continuing their oral antidia-
betics. These findings suggested that attenuation of hepatic glucagon action, 
by introducing insulin in an earlier stage of the disease and/or developing 
medication targeting the glucagon receptor, could be a promising therapeutic 
strategy for t2dm.
In chapter 5 we investigated whether the antisense gcgr-antagonist isis 
325568 has a glucose lowering effect in humans in vivo. This study was per-
formed using a double-blind, placebo-controlled, dose-escalation design, and 
evaluated the, tolerability, pharmacokinetics and pharmacodynamics of single 
and multiple dose administrations of isis 325568 at 4 dose levels in healthy 
subjects. isis 325568 is a second-generation antisense phosphorothioate oli-
gonucleotide and was designed to function through an rnase h-dependent 
terminating mechanism. In the multiple dose cohorts of this study, at each 
dose level, 8 subjects received 8 doses over 6-weeks (3 iv doses in Week 1 fol-
lowed by 5 weekly sc doses) and underwent a glucagon challenge procedure 
(glucagon infusion that doubled both plasma glucagon and glucose levels) 
at baseline and at the end of 6-week treatment. This study showed that isis 
325568 did not cause clinically significant changes in vital signs, ecg, hepatic 
or renal function and no hypoglycemia was observed. The drug was generally 
well-tolerated, with dose-dependent local injection site erythema as the most 
common adverse event. All findings were consistent with the adverse event 
profile for this class of antisense oligonucleotides [8]. Glucagon infusion prior 
to aso treatment caused a rapid 2-fold elevation of plasma glucose levels and 
hgp, which was significantly blunted by the antisense compound at the 400 
mg/week dose. No changes in plasma glucose auc or hgp were observed in 
the placebo group. Plasma trough drug concentrations after Week 4 reached 
an apparent steady-state and displayed pk-pd relationship consistent with 
preclinical data. Importantly, this study provides the first proof of pharmacol-
ogy with gcgr aso in humans, as reflected by a reduction in glucagon-induced 
glucose excursion. These results support further evaluation of aso-based 
therapies against the glucagon receptor in patients with t2dm. 
In chapter 6 a semi-mechanistic model simultaneously describing gluca-
gon, plasma glucose, insulin and glucagon receptor internalization was build 
using data from our glucagon challenge study in healthy volunteers (Chapter 
3). Although this model represents a simplification of complex physiology, the 
main counter-regulatory elements in the glucose regulation system (glucagon 
and insulin) were used to describe glucose’s profile in a semi-mechanistic way. 
Application to clinical data showed that the model is able to describe the levels 
of insulin, glucagon and glucose before and during the glucagon challenge. 
This model further elucidated the potential role of glucagon in the pathophysi-
ology of diabetes mellitus. It describes a general trend and can therefore serve 
as a basis for drug development.
In conclusion, the studies described in this thesis show that: 
 » The effect of meal replacers containing protein hydrolysate on plasma 
glucose lowering is limited in t2dm patients due to a collective increase  
of both insulin and glucagon levels;
 » The glucagon challenge test has limited variability in healthy volunteers 
and no confounding changes in ans tone;
 » t2dm patients respond profoundly different to a glucagon challenge test 
compared to healthy volunteers;
 » The response to a glucagon challenge test in t2dm subjects is influenced 
by the type of therapy (oral antidiabetics or iv insulin);
 » Proof of pharmacology in humans of the antisense glucagon receptor 
antagonist can be demonstrated by using a well-characterized glucagon 
challenge test;
 » It is possible to design a semi-mechanistic model which simultaneously 
describes glucagon, plasma glucose, insulin and glucagon receptor 
internalization using data from glucagon challenges in healthy volunteers. 
This model could contribute to a better understanding of pathophysiology 
of diabetes mellitus. 
Based on these studies, absolute or relative glucagon excess seemed to be 
critical in the development and/or maintenance of hyperglycemia in diabetes 
by increasing hepatic glucose output. Strategies targeted glucagon could be 
suitable for the improvement of glucose levels.
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The studies in this thesis provide more insight in the role of glucagon in glu-
cose homeostasis in healthy subjects and t2dm patients. It seems that the 
ideal treatment for t2dm might be multi-faceted and should include more 
than control of blood glucose levels by insulin-related therapy only. Nowadays, 
mechanisms of action, benefits, and risks of traditional and newer agents for 
the treatment of t2dm are discussed to better enable the pharmacist and doc-
tor to recommend the best combinations of agents for individual patients. 
Targeting the glucagon receptor could be a potential therapeutic option for 
the treatment of t2dm. Additional studies into the cause of the inflammatory 
(skin) reactions induced by antisense gcgr-antagonist (isis 325568) deserve 
further attention. It would be interesting and worthwhile to further refine the 
glucose homeostasis model that we developed for instance by including the 
data of t2dm patients and the effects of gcgr knock-down into the model. 
Furthermore, if an oral glucose tolerance test (ogtt) could be incorporated in 
the model, the incretin effect could be implemented to analyze the relation-
ship between glucose regulation and gip and glp-1 and glucagon. Then this 
model could be used for the glp-analogs and ddp-iv inhibitor drugs as well.
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In dit proefschrift worden diverse klinische studies beschreven die zijn ontwor-
pen om de rol van glucagon in glucose homeostase te onderzoeken bij gezonde 
vrijwilligers en type 2 diabetes patiënten (t2dm).
Bij mensen zonder diabetes mellitus vindt glucagon secretie plaats bij een 
lage glucose concentratie in het bloed. De belangrijkste fysiologische rol van 
glucagon is het stimuleren van de hepatische glucoseproductie, wat leidt tot 
stijging van plasma glucose. De werking is tegengesteld aan de werking van 
insuline en verschaft samen insuline een belangrijke rol in het handhaven 
van de glucose homeostase in vivo. Vergeleken met gezonde proefpersonen, 
hebben patiënten met diabetes een abnormale secretie van zowel insuline als 
glucagon [1-3]. Hyperglucagonemie en veranderde insuline-glucagon ratio’s 
spelen een belangrijke rol in het initiëren en onderhouden van pathologische 
hyperglycemische situaties bij diabeten. Deze waarnemingen hebben geleid 
tot een hernieuwde belangstelling voor de rol van glucagon en in het bijzonder 
glucagon (receptor) als potentieel doelwit voor de behandeling van diabetes. 
Glucagon is een van de therapeutische doelen van de incretine-gebaseerde 
therapieën. Een decennium geleden, vóór de invoering van behandeling met 
incretinen, waren er alleen insuline gebaseerde therapieën beschikbaar: 
biguaniden, sulfonylureumderivaten en thiazolidinedionen. Incretinen, glp-1 
analogen en ddp-iv remmers, stimuleren de insulineproductie en -secretie 
door de ß-cellen en remmen de glucagonproductie door de α-cellen in de pan-
creas. Geneesmiddelen die zich richten op de glucagon receptor (gcgr) zijn in 
ontwikkeling, maar small molecules zijn tot op heden niet succesvol gebleken 
vanwege de beperkte selectiviteit, verschillen tussen proefdiersoorten en de 
mens en het ontbreken van langdurige effecten na niet-competitieve blokka-
de. Isis Pharmaceuticals Inc (Carlsbad, usa) ontwikkelde een tweede generatie 
antisense oligonucleotide (aso) glucagon receptor antagonist (isis 325568). 
Deze aso werd ontwikkeld als een mogelijke behandeling voor t2dm. In gcgr 
knock-out muizen (muizen zonder glucagon receptor) was er sprake van hyper-
glucagonemie en α-cel hyperplasie, maar een verbeterde glucosetolerantie en 
de muizen ontwikkelden slechts een milde nuchtere hypoglycemie [4]. Deze 
resultaten zijn consistent met de preklinische experimenten met antisen-
se oligonucleotiden tegen de glucagon receptor. Diabetische db/db-muizen 
behandeld met deze oligonucleotiden hadden lagere glucose, triglyceriden en 
vrije vetzuren in het bloed, een verbeterde glucosetolerantie en ontwikkelden 
hyperglucagonemie zonder duidelijke effecten op de grootte en het aantal 
α-cellen in de pancreas [5]. In Zucker diabetische obese (zdf) ratten en db/
db en ob/ob-muizen was er een toename van glp-1 en insulinespiegels [6].
doel van dit proefschrift
In dit proefschrift wordt de nadruk gelegd op de rol van glucagon op de gluco-
se regulatie bij gezonde vrijwilligers en t2dm patiënten en onderzocht of een 
(antisense) glucagon receptor antagonist een nuttige therapeutische inter-
ventie kan zijn in de behandeling van t2dm. Het is complex om de glucagon 
secretie farmacologisch te beinvloeden aangezien verschillende onderdelen 
die de secretie van de α-cel stimuleren ook aanwezig zijn in ß- cellen. Om die 
reden hebben we de glucagon challenge test, beschreven door Petersen et al. 
[7], verder onderzocht en als instrument gebruikt voor de klinische studie met 
een nieuwe gcgr-antagonist.
hoofdstuk 1 bestaat uit een algemene inleiding. Dit hoofdstuk begint met 
een algemene beschrijving van de glucose homeostase, pathofysiologie van 
t2dm en de huidige behandelingsmogelijkheden. De α-cellen van de pancreas 
en glucagon secretie zijn fundamentele componenten in de glucose regulatie. 
hoofdstuk 2 bestudeert de effecten van een maaltijdvervanger bestaande 
uit een enkel eiwit hydrolysaat (insuVida™) op postprandiale plasma glucose, 
insuline en glucagon niveaus bij t2dm. Wij concludeerden dat een eenmalige 
inname van een caseïne hydrolysaat met en zonder toevoeging van leucine 
de koolhydraat-geïnduceerde insulinerespons in t2dm patiënten verbeterde. 
En dit resulteerde in significant lagere plasma glucose concentraties verge-
leken met placebo en intact caseïne. Echter, naast insuline secretie door de 
pancreas, steeg ook de glucagon concentratie tijdens het gebruik van alle 
caseïne-rijke maaltijdvervangers. Dit mechanisme kan de daling in plasma 
glucose concentratie beperken en kan verantwoordelijk zijn voor de afwezig-
heid van hypoglycemieën. Verder onderzoek is nodig om de lange-termijn 
klinische voordelen van een lage dosis insuVida™, met en zonder extra leucine 
te bepalen. Dit hoofdstuk benadrukt tevens dat het onderzoeken van slechts 
één hormoon dat betrokken is bij de glucose homeostase (in dit geval insuli-
ne), zoals werd gedaan in alle voorgaande studies bij de maaltijd vervangende 
producten, een te beperkte benadering is. Het is belangrijk dat interventies 
die gericht zijn om een gestoorde glucose-homeostase te verbeteren, volledig 
moeten worden gekarakteriseerd.
Het doel van de studie in hoofdstuk 3 was om een glucagon provocatie-
test te bestuderen als instrument voor diabetes onderzoek, door beoordeling 
van de inter-en intra-individuele variabiliteit van de glucagon provocatietest, 
en door onderzoek naar de activiteit van het autonome zenuwstelsel (ans) 
tijdens deze test aangezien dit een indirect effect op de glucose homeostase 
zou kunnen hebben. De glucagon challenge bestaat uit infusies met suprafy-
siologische dosering glucagon, insuline, en somatostatine, om de endogene 
productie van glucagon en insuline te onderdrukken. De hepatische gluco-
seproductie werd bepaald met behulp van infusie van stabiele isotopen van 
glucose. Verder hebben we onderzocht of bij mensen glucagon receptor mrna 
tot expressie komt in vetweefsel, aangezien dit dan een rechtstreekse biomar-
ker zou kunnen zijn voor het farmacologisch effect van geneesmiddelen die 
de glucagon receptor beïnvloeden. De resultaten van deze studie in 24 gezon-
de vrijwilligers toonden een snelle stijging in plasma glucose concentratie na 






glucagon infusie, en bereikte een plateau op 90 min. De tijd profielen sugge-
reren dat er sprake is van een snelle tolerantie voor glucagon-geïnduceerde 
hyperglycemie. Tijdens de glucagon provocatietest was de intra- en inter-
individuele variabiliteit voor hepatische glucoseproductie, de snelheid van 
verdwijnen van glucose en plasma glucose concentratie, ongeveer 10-15% 
voor alle variabelen. Hyperglucagonemie had geen invloed op de hartslag-
variabiliteit. In tegenstelling tot gcgr mrna expressie in diabetische muizen, 
vonden we dat de expressie van glucagon receptor mrna in het menselijk 
vetweefsel extreem laag was en niet kan dienen als een geschikte biomarker 
voor de aanwezigheid van gcgr in de mens. Uit deze studie werd geconclu-
deerd dat de gestandaardiseerde 6-uur durende glucagon challenge test een 
goede reproduceerbaarheid heeft met slechts beperkte variabiliteit gedurende 
6 weken. Het is een krachtige manier om in detail de bijdrage van glucagon bij 
normale en veranderde glucose homeostase te bestuderen en kan ook worden 
gebruikt om de effecten van geneesmiddelen met een antagonerende werking 
op glucagon te onderzoeken zonder invloed van veranderingen in autonome 
zenuwstelsel.
Op basis van deze studie werd de een robuust hulpmiddel voor glucagon 
gericht onderzoek in diabetes. In hoofdstuk 4 werden de effecten van een 
soortgelijke glucagon provocatietest zoals beschreven in hoofdstuk 3 onder-
zocht, maar dan in t2dm patiënten en vergeleken met de glucagon respons 
bij gezonde vrijwilligers. Bij de patienten groep werd door middel van een 
cross-over studie ontwerp, met of zonder orale antidiabetica, de invloed 
van verschillende orale antidiabetica tijdens de glucagon provocatietest 
onderzocht. Onze resultaten tonen aan dat de reactie op een hyperglucago-
nemische provocatietest sterk verschilt tussen t2dm patiënten en gezonde 
vrijwilligers. Gezonde vrijwilligers laten een sterkere stijging van de hgp zien 
ten gevolge van het glucagon infuus en ook een snellere daling van de hepa-
tische glucoseproductie dan t2dm patiënten. Exogene insuline onderdrukt 
de glucagon-geïnduceerde hepatische glucoseproductie. Bovendien waren 
de glucosespiegels lager tijdens glucagon provocatietest bij t2dm patiënten 
die twee weken hun orale medicatie hadden gestopt en een hogere dosis exo-
geen insuline kregen tijdens de test dan de patientengroep met voortzetting 
van hun orale antidiabetica. Deze bevindingen suggereren dat een afname van 
het effect van glucagon op de lever, door toediening van insuline in een eerder 
stadium van de ziekte en/of de ontwikkeling van geneesmiddelen gericht op de 
glucagon receptor, een veelbelovende therapeutische strategie kan zijn voor 
t2dm. 
In hoofdstuk 5 onderzochten we of de antisense gcgr-antagonist, isis 
325568, een bloedglucose verlagend effect heeft bij de mens. Dit onderzoek 
werd uitgevoerd met behulp van een dubbel-blind, placebo-gecontroleerde 
dosis-escalatie studie en evalueerde de verdraagbaarheid, farmacokinetische 
en farmacodynamische eigenschappen van enkelvoudige en meervoudige 
doseringen met isis 325568 bij gezonde vrijwilligers in 4 verschillende dosis-
niveau’s. isis 325568 is een tweede-generatie antisense fosforothioaat 
oligonucleotide en is ontworpen om te werken door gebruik te maken van het 
rnase h-mechanisme. In de cohorten met meerdere doseringen ontvingen 
acht proefpersonen 8 doseringen gedurende 6 weken (drie iv doseringen in 
week 1, gevolgd door vijf wekelijkse subcutane doseringen) en een glucagon 
provocatietest bij aanvang en aan het einde van 6 weken behandeling. Deze 
studie toonde aan dat isis 325568 geen klinisch significante veranderingen 
in de vitale functies, ecg, lever- of nierfunctie veroorzaakte en er werd geen 
hypoglykemie waargenomen. Het geneesmiddel werd over het algemeen 
goed verdragen, met een dosis-afhankelijke lokaal erytheem op de injectie-
plaats als meest voorkomende bijwerking. Alle bevindingen waren consistent 
met het bijwerkingenprofiel voor deze klasse van antisense oligonucleotiden 
[8]. Glucagon provocatietest veroorzaakte een snelle 2-voudige verhoging van 
plasma glucose concentraties en hgp, dit effect was aanzienlijk verminderd na 
6 weken behandeling met gcgr aso in dosering 400 mg/week. Er werden geen 
veranderingen in plasma glucose auc of hgp waargenomen in de placebo-
groep. De dalspiegels van het geneesmiddel in het bloed veranderde na 4 weken 
doseren niet meer omdat er kennelijk een evenwichts-concentratie (steady-
state) was bereikt en de pk-pd relatie was consistent met de preklinische 
gegevens. Deze studie met gcgr aso heeft het eerste bewijs van werkzaam-
heid bij mensen geleverd. Deze resultaten ondersteunen verdere evaluatie van 
aso-gebaseerde therapieën tegen de glucagon receptor bij patiënten met type 
2 diabetes mellitus. In hoofdstuk 6 wordt een semi-mechanistisch model 
met glucagon, plasma glucose, insuline en glucagon receptor internalisatie 
gebouwd met behulp van gegevens uit onze glucagon provocatietest studie in 
gezonde vrijwilligers (hoofdstuk 3). Hoewel in dit model de complexe fysiologie 
van glucose sterk is vereenvoudigd, werden de belangrijkste contra-reguler-
ende elementen in het glucose regelsysteem (glucagon en insuline) gebruikt 
om het glucose profiel te beschrijven. Toepassing op klinische gegevens lieten 
zien dat het model in staat is de niveaus van insuline, glucagon en glucose te 
beschrijven voor en tijdens de glucagon provocatietest. Door toepassing van 
dit model wordt de potentiële rol van glucagon in de pathofysiologie van diabe-
tes mellitus verder verduidelijkt. Het beschrijft een algemene trend en kan dus 
dienen als een basis voor de ontwikkeling van geneesmiddelen.
Concluderend, de studies in dit proefschrift tonen aan dat:
 » Het effect van maaltijdvervangers met eiwithydrolysaat op verlaging  
van de plasma glucose beperkt is in t2dm patiënten als gevolg van een 
gezamenlijke verhoging van zowel insuline als glucagon;
 » De glucagon provocatietest een beperkte variabiliteit heeft in gezonde  
vrij willigers en niet wordt beinvloed door veranderingen in autonome 
zenuwstelsel; 
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 » t2dm patiënten reageren totaal anders op een glucagon challenge test  
in vergelijking met gezonde vrijwilligers;
 » De reactie op een glucagon challenge test in t2dm patiënten wordt 
beïnvloed door het type behandeling (orale antidiabetica of insuline iv);
 » De werkzaamheid van antisense glucagon receptor antagonist in mensen 
is bewezen en kan worden aangetoond met behulp van een goed 
gekarakteriseerde glucagon provocatietest; 
 » Het is mogelijk om een semi-mechanistisch model te ontwerpen dat  
gelijktijdig glucagon, plasma glucose, insuline en glucagon receptor  
internalisatie beschrijft, op basis van de resultaten van de glucagon 
provocatietest bij gezonde vrijwilligers. Dit model kan bijdragen tot  
een beter begrip van de pathofysiologie van diabetes mellitus.
Een absoluut of relatief glucagon overschot is een cruciale oorzaak voor het 
ontwikkelen en onderhouden van hyperglycemie bij patiënten met diabe-
tes mellitus door het stimulerende effect op de hepatische glucose output. 
Strategieën gericht tegen glucagon kunnen geschikt zijn voor het verbeteren 
van glucose regulatie.
vooruitzichten
De onderzoeken beschreven in dit proefschrift bieden meer inzicht in de rol 
van glucagon in glucose homeostase bij gezonde proefpersonen en t2dm pati-
enten. Het lijkt dat de optimale behandeling voor t2dm veelzijdig is en niet 
alleen insuline-gerichte therapie moet bevatten voor een evenwichtige gluco-
se regulatie. Vandaag de dag worden de werkingsmechanismen, voordelen en 
risico’s van traditionele en nieuwere middelen voor de behandeling van t2dm 
besproken om de apotheker en arts beter in staat te stellen de beste behandel-
combinaties voor individuele patiënten voor te schrijven. Therapieën gericht 
op de glucagon receptor zouden een mogelijke aanvullende behandeling zijn 
voor t2dm patiënten in de toekomst. Aanvullend onderzoek naar de oorzaak 
van het ontstekingsreacties (huid) geïnduceerd door antisense gcgr-antago-
nist (isis 325568) verdienen nog aandacht. In de nabije toekomst zou het nog 
interessant en nuttig zijn om het door ons beschreven glucose homeostase 
model verder te verfijnen door de gegevens van t2dm patiënten en de effecten 
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